Agonist Binding Studies at Two Subtypes of the Nicotinic Acetylcholine Receptor Involved in Parkinson’s Disease and Addiction by Post, Michael Robert
Agonist Binding Studies at Two Subtypes of the 
Nicotinic Acetylcholine Receptor Involved in 
Parkinson’s Disease and Addiction 
 
 
Thesis by 
Michael Robert Post 
 
In Partial Fulfillment of the Requirements for 
the degree of 
Doctor of Philosophy 
 
 
 
 
CALIFORNIA INSTITUTE OF TECHNOLOGY 
Pasadena, California 
2016 
(Defended  27 May, 2016)
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2016 
Michael R. Post 
ORCID: 0000-0002-3214-7619 
 iii 
Acknowledgements 
 While the scientific work presented in this dissertation filled the bulk of the last 
five years, it is the following people who have infused them with value and meaning.  There 
are countless individuals who have made my time at Caltech exceptional, but several 
demand special thanks: 
Dennis Dougherty for his unwavering support and mentorship.  From the moment 
he became my advisor, Dennis has encouraged me to think critically and creatively about 
my work.  He has been an ideal advisor – letting me explore both scientific and 
extracurricular passions while constantly maintaining an open door and a willingness to 
push me to reach my fullest potential.  He has allowed and encouraged me to pursue the 
most far-fetched of ideas, from incorporating δ-amino acids to chairing the GSC, and I 
cannot imagine having worked with anyone else.  Dennis will serve as a paradigm as I 
begin to shape my own path in academia; 
Henry Lester, for having such a meaningful impact on the direction of both my 
science and my career.  His input at our monthly Unnaturals meetings has shaped the work 
in this thesis for the better.  I thank him for thinking of me whenever an opportunity to 
collaborate arose and for providing me with thoughtful and honest advice while I was 
looking for post-doctoral opportunities; 
The members of my thesis committee for giving focus and direction to my doctoral 
work.  Jackie Barton and David Tirrell have given me thoughtful input at our annual 
meetings and exams, and I am grateful for Sarah Reisman’s approachability as chair of the 
committee.  I would also be remiss to not mention Linda Syme for keeping the lab in proper 
 iv 
functional order and Agnes Tong for always lending a supportive ear and making me feel 
welcome my first days at Caltech; 
Carla Swick, William Shelley, Deni Ors, and the late Michael Stuart for kindling 
my love for science.  They were the amazing teachers in middle and high school who 
encouraged me to go above and beyond the material they taught, giving me extra 
opportunities to learn and introducing me to scientific research;  
Joshua Maurer, for giving me the opportunity to work in his lab during my time at 
Washington University in St Louis.  His creative ideas and approaches showed me there 
are no limits in how to solve a complex problem, and his lab introduced me to chemical 
biology and its use in studying neuroscience; 
The entire Dougherty lab, of which I’m certain there is no better environment to 
spend five years of graduate school in.  This group is full of so many fun and talented 
people, and no matter what state my science was in, because of them I have always looked 
forward to heading into lab.  Kay Limapichat showed me the ropes – everything from how 
to linearize DNA to the importance of green clips.  She showed me by example how to 
thoughtfully and thoroughly approach a scientific problem.  Ethan van Arnam also served 
as an example of the consummate scientist, tackling projects head on with innovative ideas 
and a positive if not sarcastic attitude. Noah Duffy, Kristina Daeffler, and Tim Miles 
formed the foundation of the North Bay Nation, and my interior years in grad school would 
not have been the same without them.  Noah was always the one to get things done and I’m 
lucky he taught me some of his MacGyverish ways. Kristina was my biggest role model 
and one of my best friends in the lab – I knew I could always turn to her for help and expect 
real and honest advice.  Tim is also a great source of inspiration and friendship – I will 
 v 
always appreciate how well-read he is, whether it be in Nature, the New York Times, or 
Pitchfork.  Clint Regan has shown me how to approach a scientific problem with rigor, 
Ximena da Silva showed me how to perform single channel analysis, and I will always 
cherish my conservations with Betty Wong about GSC politics.  Oliver Shafaat is someone 
I always seem to find myself with in deep conversation, and I am always impressed with 
his dedication to doing something new and novel in this lab.  Chris Marotta will forever be 
my co-Opus captain and Tryptoman coach.  Chris was a year ahead of me and left footsteps 
I was eager to follow in.  Whether in a clown mask or a business suit, Paul Walton knows 
exactly how to brighten my day.  He is a brilliant scientist and I look forward to seeing all 
the great things he accomplishes.  Annet Blom is a wonderful person who I am so glad to 
have gotten to know so well.  We have such similar philosophies about Caltech and the 
world and share a similar penchant for creating Latin phrases.  Catie is another lab member 
who shares a similar world-view, and I always enjoy our humanities-oriented conversations 
in a sea of scientific thought.  Bryce Jarmin has always strove to do science beyond the 
limits of what we have traditionally done in the group, a trait I admire.  He also shares my 
passion for overproduced music and enablement; I am glad the group will continue to have 
someone encouraging keynote games and rooftop Fridays.  Richard, Steve, and Malaney 
are the future of the Dougherty lab and appear primed to continue the amazing environment 
that has come before them.  I have also had the pleasure of mentoring Gabby Tender for 
the last two years.  From the start, when she was just a freshman, I knew Gabby was an 
exceptional undergraduate.   She knows exactly what questions to ask and works incredibly 
hard.  I am grateful for the opportunity to have mentored her and all that she has contributed 
to our project together, and cannot wait to see what path she takes in the scientific world; 
 vi 
Matt Rienzo and Matt Davis, for embodying the epitome of what it means to be 
both a colleague and a friend.  Matt Rienzo joined the lab weeks before I did, and has taught 
me so much and helped me grow in both lab and life.  More than any other grad student, 
he has helped me become more confident as a scientist and a person.  Whether 
exasperatingly ranting about the downs together, or excitedly celebrating the ups, I am 
lucky to have joined the lab with someone like him.  Not only has Matt Davis been one of 
my best friends in grad school, he has also been one of my closest collaborators.  Our 
project together was a long and interesting one, and I am grateful for how easy it was to 
share ideas and get things done.  Matt and his other half, Rachel Sparr, have become my 
California family, and from baseball games to Shabbas dinners, our time spent together is 
always awesome; 
The graduate student council and all of its members for giving me an outlet to do 
what I love outside of the lab.  I have been very fortunate to have had leadership roles in 
such a great organization, and even luckier to have stumbled across Joel Schmidt, Sunita 
Darbe, and Max Lloyd in the process.  I always valued working with them in the GSC and 
becoming such great friends outside of it was even better.  I was also fortunate to have been 
advised by Joe Shephard and Anneila Sargent while serving as chair.  I could always count 
on their sagacious advice, and I thank them for providing an example of how to be leaders 
on a campus while part of the professoriate.  Felicia Hunt also served as a mentor 
throughout my time in the GSC and words cannot describe how much of an impact she has 
had on my time here.  I am forever thankful of how much support and care she graciously 
gave me throughout my time here; 
 vii 
Alli Akagi, Tania Darnton, Brandon Carroll, and Julian Edwards, for being such 
amazing friends.  I will always remember sitting in NMR class and awkwardly asking if I 
could hang out with Tania and Alli when overhearing their plans.  From there a beautiful 
friendship blossomed with each of them.  Tania is the ultimate stitcher-in-arms and I am 
never afraid to confide in her about even the most important or trivial of matters.  I will 
miss being able to walk down the hall to talk to Alli about whatever is on my mind and 
whether we are at the Red Door or a pool table, we always have the best time together.  
Julian was gracious enough to include me in his annual pilgrimage to Telluride our first 
year, and from then on I knew I had found a life-long friend.  Our hyperintellectual rants 
about the most mundane of things are typically the best part of my day and I look forward 
to whatever epicness the future holds for him; 
Carl Blumenfeld, Brett McGuire, Adam Boynton, and Larry Dooling for fostering 
the perfect home-life.  These gentleman have been my roommates at various times 
throughout grad school, and as much as I looked forward to getting into lab, I have always 
looked forward more to heading back home at the end of the day because of them.  Carl 
was one of my first friends at Caltech and is the best at adventuring and making you feel 
like you have known him forever.  Brett introduced me to so many things, from Game of 
Thrones to fitness, and my life is much fuller because of him.  Boyntz has a knack for 
sending me a fresh new track right when I need it, and his down-for-whatever attitude has 
made for two solid years of living at the Orange Grove estate; 
Anna Henkel, Jeremy Carlson, David Ingber, and Ricky Steiner for having 
remained so close after college, even when I moved so far away.  That I can still dial any 
of them to help make important life decisions or to just catch up, no matter how much time 
 viii 
has elapsed since the last call, means the world to me.  I feel like our friendships have only 
grown stronger since our days at Wash U, and I am lucky to still have you all a part of my 
life; 
Jordan Forman, for making the last year of graduate school so unexpectedly special.  
Jordan has caused me to live G5 to the fullest, instead of crammed in a lab or an office, and 
I really value the time we have spent together so far; 
My brother and sister, though it could easily go unsaid, for being such a massively 
important part of my entire life.  Jennie has been my idol growing up; I always wanted to 
be just like her whether it was in band, BBYO, school, or camp, and I specifically 
remember sitting in the SHS auditorium at her senior research symposium thinking I 
wanted to do that one day.  Now that I have gotten a taste of science and research, I realize 
how grateful I am for having such a powerful role model throughout my life.  Not only 
that, she has been so supportive throughout grad school and I do not know what I would 
do without her and Ben.  My brother Daniel has been my twenties spirit guide, serving as 
a never-ending source of wisdom for how to live my life.  I’m so appreciative of all of the 
advice he’s given me throughout the years, of how close we have gotten as I’ve grown 
older, and of his yearly summer trips to the west coast.  I cannot wait to be just a short 
subway ride away from him in the coming years and the adventures that I am sure will 
ensue; 
And finally my parents, because for all of the passion-kindling those mentioned 
already have done, it was my mom and dad who set off the initial spark.  Though not 
scientists themselves, they always encouraged me to learn more, ask questions, and explore 
my environment.  From giving me and my siblings free range of the local creek and cages 
 ix 
to keep salamanders in, to Magic School Bus toys and books about space, to underwater 
slide shows and trips to the aquarium or science center, my parents from early on provided 
me the foundation for a career in science.  As I grew older, their support never waned, as 
toothpick bridges turned into science fair boards into research posters and talks.  Their 
simultaneous phone calls on their way home from work have kept me going throughout 
grad school, although I will be happy when the frog egg dad-jokes cease.  I am who I am 
today because of them, and for that I am forever grateful. 
  
 x 
Abstract 
 Neuronal nicotinic acetylcholine receptors (nAChR) consist of pentameric ligand 
gated ion channels that typically regulate the release of neurotransmitter.  This group of 
receptors is made of many subunits that combine into pentamers to form different subtypes, 
with each subtype having a unique pharmacology, function, and localization in the nervous 
system.  The α6β2 subtype is found predominantly in the dopaminergic pathways in the 
brain, and is therefore a promising target for addiction and Parkinson’s disease.  A major 
goal in treating these disorders is to develop subtype-selective agonists, and advanced 
knowledge of the binding site which sits at the α6-β2 subunit interface is critical.  This 
thesis dissertation describes high precision, chemical scale structure-function studies 
designed to probe specific interactions between a variety of agonists and the amino acids 
which make up the α6β2 binding site.   
 Before these studies, which utilize nonsense suppression-based non-canonical 
amino acid mutagenesis, could be conducted, a heterologous expression system for α6β2 
had to be developed.  Chapter 2 details four reporter mutations that allow high expression 
levels of α6β2 in Xenopus oocytes.  Further work presented in this chapter characterizes a 
variety of compounds at this subtype including acetylcholine, the endogenous agonist, 
nicotine, and TC299423, a promising drug candidate designed to be α6-selective. 
 Chapters 3 and 4 discuss the structure-function studies used to probe for binding 
interactions of acetylcholine, nicotine, and TC299423 with the α6-β2 interface.  
Fluorination series were executed to probe for cation-π interactions with TrpB, TyrA, and 
TyrC2, all sites of the α6 face.  Of the nine possible agonist-side chain interactions, the 
 xi 
only functionally important cation-π interaction was found between acetylcholine and 
TrpB, suggesting the subtype has a unique pharmacology.  Studies utilizing α-hydroxy 
acids were then performed to determine whether these agonists make a functional hydrogen 
bond between their amine NH and the backbone carbonyl associated with TrpB.  Here, 
nicotine was found to make a strong hydrogen bond, whose energy was quantified via 
double-mutant cycle analysis, but TC299423 was not. 
 Chapter 5 further explores TC299423 at the α4β2 subtype.  Experiments here 
showed that TC299423 makes a dual cation-π interaction with both TrpB and TyrC2.  
Further studies revealed this dual cation-π effect to be true for several secondary amines, 
and a structure-function study with nornicotine established this as a general feature for 
secondary amines.   
Chapter 6 describes work done to probe for a hydrogen bond between the indole 
NH of α4 TrpB and a backbone carbonyl associated with L119 on the β2 subunit.  This 
study required development of a new strategy to probe for hydrogen bonds as the amino 
acid sequence does not allow for α-hydroxy substitution.  Instead, a fluorinated side chain 
strategy was used to inductively attenuate the hydrogen bond accepting ability of the 
carbonyl, and it proved the α4-β2 interfacial hydrogen prediction false. 
Finally two appendices suggest possible avenues to explore with the new α6β2 
expression system.  Appendix A describes work done to determine whether there is cross-
talk between α6β2 and P2X receptors.  Appendix B details initial investigations on the 
effects of ethanol and other alcohols on the function of α6β2. 
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Chapter 1: Introduction 
 Nicotine addiction and Parkinson’s disease remain major public health issues in the 
United States.  According to the Centers for Disease control, twenty percent of Americans 
smoke.1  Of those smokers, eighty percent smoke every day, and three quarters smoke one 
half to one whole pack of cigarettes per day.2  Another recent survey showed that in the 
previous thirty days, nearly three million middle school and high school students reported 
using an e-cigarette.3  While the long term effects of e-cigarettes are largely unknown, 
health issues related to smoking generate 96 billion dollars in costs per year, and smoking 
is the greatest cause of death in the U.S. – more than alcohol, drugs, homicide, car 
accidents, and AIDS combined.4  As nicotine is a recreational drug, its negative impact on 
health is mostly preventable; however, while sixty percent of those smokers surveyed 
above expressed a desire to quit, only fifteen percent actually did.5  This is because nicotine 
is highly addictive. 
Parkinson’s disease, on the other hand, is not preventable.  This neurodegenerative 
disorder is characterized by severe motor issues including tremor, postural imbalance, 
slowness of movement, and rigidity.  It affects nearly one million Americans with 60,000 
new diagnoses every year, a number expected to double by 2030 as the baby boomer 
generation ages.6  One of the many challenges Parkinson’s disease presents is that by the 
time it is detectable, between sixty to eighty percent of neurons in the midbrain have died, 
a major reason why both an etiology and a cure remain elusive.7 
Nicotine addiction and Parkinson’s disease are linked to the mesocorticalimbic and 
nigrostriatal dopaminergic pathways, respectively (Figure 1).  The mesocorticolimbic 
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pathway, the pathway central to addiction, starts in the ventral tegmental area and extends 
into both the nucleus accumbens, which is responsible for reward, and the cortex, an area 
responsible for decision making.  The nigrostriatal pathway, which starts in the substantia 
nigra pars compacta and extends into the dorsal striatum, contains the neurons responsible 
for motion, which are the cells that die in the course of Parkinson’s disease.  Because both 
disorders revolve around the dopaminergic pathways, they are intricately linked.  In fact, 
smoking cigarettes has shown a neuroprotective effect.  This phenomenon has been 
documented in studies involving sets of identical twins in which one smokes and one does 
not, where the former is less likely to develop Parkinson’s disease than the latter.8,9  While 
the specific cause of this effect is unknown, it is likely due to the fact that dopamine release 
is regulated by the cholinergic system and its neurotransmitter, acetylcholine (ACh). 
Nicotinic acetylcholine receptors (nAChRs), the primary target of ACh released by 
cholinergic neuron inputs, are found at synapses at both ends of a dopaminergic neuron 
Figure 1. A schematic of the mesocorticolimbic and nigrostriatal dopaminergic pathways.  The inset is a 
simplified cartoon of how dopamine release is regulated by acetylcholine receptors at both the dendritic 
end (such as in the substantia nigra) and the axonal end (such as in the striatum). 
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(Figure 1, inset).10  On the dendritic end, they are on presynaptic neurons which release of 
excitatory glutamate (Glu) and inhibitory (GABA) and therefore govern the signals the 
dopaminergic system receives by these inputs.  On the axonal end, nAChRs are found on 
the presynaptic terminals of the dopaminergic neurons, and control the release of dopamine 
into the synapse which then activates medium spiny neurons.11  Thus, nAChRs are 
responsible for modulating the release of dopamine, and understanding how both 
acetylcholine and other nAChR agonists, such as nicotine, bind to the receptors is important 
to understanding how to better treat the diseases associated with these pathways. 
1.1 nAChR overview 
Nicotinic acetylcholine receptors are members of the pentameric ligand-gated ion 
channel (pLGIC) family, which also includes receptors for serotonin (5HT), glycine, and 
γ-aminobutyric acid (GABA).12  All members of this family are transmembrane proteins 
and share a similar topology (Figure 2).  As the name suggests, five subunits combine 
Figure 2. A look at the general topology of the nAChR subunit.  The view on the left is from the side and 
is modeled by the cartoon in the center.  The view on the right is looking top-down at the extracellular 
face.  Structures are from a cryo-EM structure of the Torpedo ray nAChR, PDB 2BG9. 
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around a central ion-conducting pore that opens upon agonist binding, allowing ions to 
flow across the membrane.  Each subunit has three major domains.  The first is an N-
terminal ligand-binding domain, with the agonist binding site forming at the interface of 
two subunits.  Next is a transmembrane domain composed of four alpha helices, labeled 
M1-M4.  The M2 helix lines the channel pore and serves as the channel gate, nearly 60 Å 
away from binding site.13  Third, is an intracellular domain, consisting mostly of the M3-
M4 loop; it is the most highly variable across subunits.14  This region is thought to be 
involved in transport of the protein from the endoplasmic reticulum to the plasma 
membrane.15 
 In humans, there are 16 different 
nAChR subunits expressed: α1 through α7, 
α9, and α10, β1 through β4, γ, δ, and ϵ.16,17  
These subunits form pentamers in different 
combinations, with each stoichiometry 
making up a unique subtype (Figure 3).18  
Each subtype has a unique pharmacology, 
function, and localization.19  The α1β1γδ 
and α1β1γϵ subtypes are muscle-type, and are found at the neuromuscular junction, while 
the remaining subtypes are found at synapses in both the central and peripheral nervous 
systems.  Among the neuronal subunits, α4β2 and α7 are the most expressed in the brain, 
found in almost every region.20  Other neuronal subtypes are more localized, such as those 
containing α6β2, which are found mainly on presynaptic terminals of dopaminergic 
neurons.21 
Figure 3. The sixteen different nAChR subunits 
can combine to form many different subtypes, 
examples of which are shown here.  Binding sites 
form at the interface of a primary (+) and 
complementary (-) face typically between α and β 
subunits and are indicated by a gray box. 
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 Because α6β2-containing subtypes are localized to the areas responsible for 
addiction and Parkinson’s disease, they are an important target for therapeutics.22 However, 
a major challenge in neuropharmacology is to design agonists that can selectively target 
just one nAChR subtype.23  By creating a compound that activates α6β2 subtypes while 
avoiding α4β2 and α7, the effect of that candidate can be contained within a specific 
neuronal pathway; thus, avoiding side effects which may make it ultimately untenable as a 
drug.  One strategy to overcome this challenge is to develop detailed binding maps of each 
subtype that highlight differences across the subtypes.  Such pictures have been developed 
for the α4β2, α4β4, α7, and muscle subtypes.  Chapters 2, 3, and 4 of this thesis describe 
progress toward creating a binding model for the α6β2 subtype with the goal of 
distinguishing differences in the α4-β2 and α6-β2 binding interfaces. 
In α4β2, and most of the other nAChRs studied to date, the binding site is at the 
interface of the primary α face and complementary β face.  This site is made of six loops – 
A, B, and C, from the primary face, and D, E, and F from the complementary face – that 
Figure 4. Left: a view of nicotine in the aromatic box binding site of AChBP.  Right: a summary of the 
three noncovalent binding interactions between nicotine and α4β2 previously found to be functionally 
important.  These are hydrogen bonds in purple and blue, and a cation-π interaction with TrpB in green. 
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contribute a cluster of aromatic residues, deemed the aromatic box.24,25  These aromatic 
residues are highly conserved across all PLGICs and consist of a tyrosine residue on loop 
A, a tryptophan residue on both loops B and D, and two tyrosine residues on loop C.26  
Loop C is thought to be particularly mobile, and likely moves toward the cluster during 
agonist binding, causing a conformational shift in the protein which eventually leads to 
gating.27  In the α4β2 binding pocket, three specific noncovalent interactions have been 
found functionally important for agonist binding.28   
The first is a cation-π interaction between the agonist – the typical nAChR agonist 
is a cation – and the tryptophan on loop B, often designated TrpB or Trp149.  The cation-
π interaction is an electrostatic interaction between the positive electrostatic potential of 
the agonist, and the negative electrostatic potential concentrated in the center of the 
aromatic side chain.29,30  Not only has a cation-π interaction at TrpB been found to be 
critical in every agonist tested in α4β2,31,32 the same is true with α4β4 nAChR subtypes,33 
the serotonin type A receptor with several agonists and antagonists,34,35 with agonists at a 
tyrosine in the same site in the ρ subtype of GABAA receptor,36 and a phenylalanine in the 
glycine and ELIC receptors.37–39 
The other important noncovalent binding interactions in α4β2 are hydrogen bonds 
between the agonist and the protein backbone.  The first hydrogen bond only applies to 
agonists with non-quaternary amine group, such as nicotine, where the NH group binds 
with the backbone carbonyl associated with TrpB.  In α4β2 this interaction was shown for 
nicotine, varenicline, and cytisine, but as expected not acetylcholine.31,32  This hydrogen 
bond was also seen with nicotine in the α4β4 subtype.40  The other hydrogen bond occurs 
between the other end of the agonist and a backbone NH associated with Leu119 on β2 
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loop E.40,41  In α4β2, the carbonyl group of acetylcholine and cytisine, and the pyridine 
nitrogen of nicotine were shown to make this functionally important hydrogen bond.  It 
was also demonstrated with cytisine in α4β4, as well as with acetylcholine and nicotine in 
muscle-type.34 
Together, as summarized in Figure 4, these three interactions make up the three 
most important binding interactions between an agonist and the α4β2 nAChR binding 
pocket.  Much of the work described in this thesis seeks to either add more detail to the 
α4β2 binding model as in Chapters 5 and 6 or to describe and distinguish the α6β2 model 
compared to the one outlined above as in Chapters 2 through 4. 
1.2 The Structure-Function Study as a Means of Probing Noncovalent 
Interactions 
 Historically, there has been a dearth of structural data for the pLGIC family.  Most 
of the detail about agonist binding at these receptors described in the previous section has 
instead come from biochemical experiments and structure-function studies.  Results from 
these experiments were later confirmed by a cryo-electron microscopy structure of the 
Torpedo electric ray muscle-derived nAChR13 at 4 Å, solved in 2003, and  crystal structures 
of the acetylcholine binding protein (AChBP), a soluble protein homologous to the 
extracellular binding region of the nAChR, that have been solved with many different 
ligands. In recent years, there has been a rapid increase in published pLGIC structures.  
Discoveries of prokaryotic homologues ELIC42 and GLIC,43,44 and their corresponding 
structures in 2008 and 2009, were followed with successful structural studies of an 
invertebrate glutamate channel45 in 2011, mouse serotonin receptor46 in 2015, and human 
GABA47 and glycine48 receptors in 2014 and 2015. 
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Even with this new wealth of structures, it is important to recognize their 
limitations.  Importantly, the only published nAChR structures are of homologous non-
neuronal invertebrate subtypes.  Furthermore, cryo-EM and crystal structure solutions 
merely present a snapshot of the receptors in a single conformational state, and not 
necessarily one that is biologically relevant.  They fail to take into account the dynamic 
nature of an allosteric protein such as those which make up the pLGIC family.  Therefore, 
while they are able to predict noncovalent interactions, the functional importance of these 
predictions must be verified by experimentation in a living cell system.  The classical 
experiment to probe for noncovalent interactions is the structure-function study.  For the 
nAChR binding site, this means making a small perturbation to protein structure through 
site-specific mutagenesis, and monitoring any corresponding shift in binding.  Such 
changes are measured with EC50, the effective concentration of agonist required to elicit a 
half-maximal response from all expressed receptors. 
Structure-function studies with nAChRs are performed in oocytes derived from 
Xenopus laevis, an African clawed frog.  This type of expression system is ideal because 
the cells are large enough to inject with a solution containing RNA and to impale with 
electrodes, characteristics which are utilized in the determination of an EC50 (Figure 5).
49  
First, mRNA coding for each of the subunits in a specific nAChR subtype, prepared in 
vitro, is injected into the oocyte.  Then, during an incubation period, the cell machinery 
translates that mRNA into proteins, folds and assembles them into pentamers, and traffics 
them to the plasma membrane.50  Once a sufficient level of nAChRs has been expressed 
and trafficked to the surface, channel function is monitored using two-electrode voltage 
clamp (TEVC) electrophysiology.51  In this type of experiment, a voltage electrode and a 
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current electrode are both impaled into one oocyte.  The former monitors the voltage across 
the membrane, while the latter is able to inject a variable current in order to hold the voltage 
across the membrane to a set value.  Thus, when the cell is clamped at a specific voltage, 
and agonist is applied, the total amount of current flowing into the whole cell can be 
measured. 
EC50 measurements are determined from a dose response experiment.  In a dose 
response experiment, agonist is applied in increasing concentrations until a saturated 
response is achieved.  The current measured at each dose is normalized against the 
maximum current achieved and then plotted against concentration to form a dose response 
Figure 5. A schematic detailing the process for determining an EC
50
.  Starting at the top right, mRNA of 
the desired nAChR subunits is injected into Xenopus oocytes.  After incubation, the channels are 
expressed and can be studied using TEVC electrophysiology.  The bottom left shows ACh-induced 
currents in α6β2 at increasing concentrations, the results of which have been normalized and plotted on 
the bottom right and fit to the Hill equation. 
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curve.  These data get fit to the Hill equation where Inorm = 1/(1 + (EC50/[agonist])
nH), and 
nH is the Hill coefficient.  To determine changes in binding, a dose response experiment is 
performed for both the wild-type and mutant nAChRs and a quantitative fold-shift in EC50 
is calculated by dividing the mutant EC50 by the wild-type EC50.  An increase in EC50, 
shown by a fold shift greater than one, means more agonist is required to activate the same 
number of receptors and that the mutation has caused a loss of function.  A decrease in 
EC50, shown by a fold shift less than one, means less agonist is required to activate the 
same number of receptors and therefore indicates a gain of function mutation.  A fold-shift 
of one describes a case where a change in function has no effect on function.  Thus, 
mutating specific residues predicted by structure or homology to be involved in 
noncovalent interactions and comparing their EC50 to wild-type can determine whether 
those interactions are indeed functionally important. 
1.3 Non-canonical Amino Acid Mutagenesis  
Traditionally in a structure-function study, the mutation is made to the protein using 
conventional mutagenesis, wherein a single amino acid is site specifically substituted with 
another one of the twenty naturally occurring amino acids.  This type of substitution can 
be used to, for example, entirely remove side chain functionality of an amino acid by 
switching it to an alanine.  The process is fairly straightforward in a nAChR.  The codon 
of the residue of interest is simply changed to the desired amino acid in the cDNA of the 
subunit, and the process described in the previous section resumes as usual, with the 
injected mRNA transcribed from the mutated cDNA. 
Conventional mutagenesis, albeit useful, is also quite limited.  If the targeted 
binding interaction was a cation-π interaction with TrpB, the perturbation made from 
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substituting a tryptophan to an alanine is a large one, and though a resulting loss of function 
from this mutation might suggest a cation-π interaction, it would be impossible to rule out 
the effect that shift in steric bulk has on the binding pocket.  Furthermore, because 
conventional mutagenesis can only affect the side chain, it does not provide any means for 
probing hydrogen bonds with the protein backbone.  Nonsense suppression-based, non-
canonical amino acid mutagenesis, however, offers a solution to these problems.52  In this 
method, the residue of interest is replaced with an amino acid outside the canonical twenty.  
In theory, the method is only limited by what can be synthesized in the chemistry lab.  In 
practice, this technique has been used to incorporate over 100 non-canonical amino acids 
in over 20 different ion channels. 53 
Non-canonical amino acid mutagenesis utilizes nonsense suppression, where the 
codon of the amino acid of interest is mutated to stop codon, and a suppressor tRNA inserts 
the amino acid during translation (Figure 6).54  The cDNA of the gene is mutated to a stop 
codon at the residue of interest and the gene is then transcribed in vitro and injected into 
Xenopus oocytes alongside a suppressor tRNA preloaded with the desired non-canonical 
amino acid.  This tRNA, also prepared in vitro, has an anticodon which recognizes the stop 
codon mutation and has been engineered to be bioorthogonal to the oocyte’s endogenous 
tRNA synthetases.55  The non-canonical amino acid is synthesized with a dinucleotide 
(dCA) appendage, which is then enzymatically ligated to a shortened version, or 74-mer, 
of the bioorthogonal tRNA.  With this design, the tRNA will recognize the stop codon 
during translation, the ribosome will then insert the non-canonical amino acid into the 
nascent strand, and the used tRNA will be unable to get recharged by a canonical amino 
acid, thereby ensuring the only amino acid in the site of interest is the non-canonical one. 
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Figure 6. Top: T4 ligase is used to enzymatically append NVOC-protected dCA-amino acid to a 74-mer 
suppressor tRNA.  Bottom: this tRNA-AA is injected alongside stop codon mutated mRNA into oocytes, 
wherein the ribosome takes over and inserts the amino acid into the nascent strand of the gene. 
 13 
To ensure the final protein has the non-canonical amino acid incorporated, several 
controls are necessary.  As a negative control, just the 74-mer tRNA is injected with the 
mRNA containing the stop codon mutation.  In this case, translation would likely end at 
the stop codon, and running a dose response experiment ensures that this truncated protein 
is not viable.  In an additional negative control, non-acylated but full length 76-mer tRNA 
is injected with the mRNA to check for reaminoacylation.  If this control works, and there 
is no reaminoacylation of the 76-mer, then there should be no agonist-evoked current. 
As previously mentioned, once the tRNA has been used in the ribosome, it becomes 
inert.  Because of this, the tRNA behaves as a stoichiometric reagent in the translation 
process, and the amount of protein produced takes a large hit compared to conventional 
mutagenesis.  Thus, experiments utilizing this chemical acylation method of nonsense 
suppression must be able to amplify the eventual read out.  Although some nAChR 
subtypes are harder to express than others in their wild-type form and require mutations to 
be made that will increase expression levels and current without affecting binding,56 TEVC 
electrophysiology is typically a sensitive enough technique to detect small amounts of 
protein made. 
1.4 Thesis Summary 
 The primary focus of the work presented in this thesis is focused on developing a 
binding map for α6β2 in an effort to both advance our knowledge of nAChR function and 
to establish differences in binding between α6β2 and α4β2.  The first step toward this goal 
was to develop a heterologous α6β2 expression system in Xenopus oocytes, described in 
Chapter 2.  With a set of mutations that allowed consistently high expression levels, the 
next step was to determine whether the binding interactions found to be important in α4β2 
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are functionally relevant in α6β2.  Chapter 3 details structure-function studies aimed at 
probing cation-π interactions with three aromatic residues while Chapter 4 investigates 
hydrogen bonding between agonists and the carbonyl associated with TrpB. 
 In the process of pursuing these goals, some interesting characteristics about α4β2 
became apparent that warranted further investigation.  Chapter 5 probes several agonists 
that have been found to make a cation-π interaction with both TrpB and TyrC2 in α4β2.  It 
seems likely that this is a general feature of secondary amines, as tertiary and quaternary 
amines only make a cation-π interaction with TrpB.  Finally, while most of this thesis has 
involved agonist-protein interactions, Chapter 6 details work done to probe for a 
functionally important hydrogen bond across the α4 and β2 subunits, between the NH of 
the Trp B indole ring, and a backbone carbonyl on loop E.  No such hydrogen bond was 
observed, but a new hydrogen bond structure-function study approach was developed. 
 The structure-function studies outlined above and discussed fully in this thesis 
reveal intricate details about how agonists bind, and how this binding differs at each 
subtype.  The nAChR family plays an important role in cognitive function, and the α6β2 
subtypes are important targets in both addiction and Parkinson’s disease research; however, 
there are many subtypes, each with a different role.  To truly tap into the potential of the 
nicotinic acetylcholine receptors as a drug target, each subtype must be distinguishable.  
With the work presented in the remaining chapters, we have come closer toward achieving 
that goal.  
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Chapter 2: Heterologous Expression of α6β2 nAChRs* 
2.1 Abstract 
 In order to perform structure-function studies at the α6-β2 nAChR binding interface 
using the chemical acylation nonsense suppression method, a heterologous expression 
system must be used where cells produce consistently large agonist-induced current 
waveforms with an ideally square shape.  Historically, α6β2 has presented several 
challenges, as the wild-type subunits produce no functional receptors when expressed 
Xenopus oocytes.  This chapter discusses four reporter mutations to the wild-type receptor 
– one in the α6 M2 helix, one in the β2 M2 helix, and two in the β2 M3-M4 loop – to create 
the construct deemed α6β2‡.  This results in a receptor population that produces large 
agonist-induced currents and monophasic dose response curves.  Once developed, α6β2‡ 
was optimized and characterized.  Experiments were performed that varied the injected 
mRNA ratio of α6 to β2, demonstrating there are likely two possible stoichiometries able 
to be expressed in oocytes.  However, only the α6-biased injection yields a dose response 
curve with a high Hill coefficient and a monophasic curve, suggesting the β2-biased 
responses are from a mixed population of subtype stoichiometries.  A broad panel of 
agonists that typically activate other nAChR subtypes was then surveyed against α6β2‡, 
and all of the compounds studied proved to be efficacious, with little attenuating effects on 
a post-agonist acetylcholine dose.  With α6β2‡ characterized and fully optimized, it has the 
potential to be an invaluable tool for studying pharmacology of the α6β2 subtype, and the 
                                                 
* A portion of the work presented in this chapter is adapted, with permission, from: 
Post, M. R., Limapichat, W., Lester, H. A. & Dougherty, D. A. Heterologous expression and nonsense 
suppression provide insights into agonist behavior at α6β2 nicotinic acetylcholine receptors. 
Neuropharmacology 97, 376-382 (2015). doi:10.1016/j.neuropharm.2015.04.009 
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construct will be used in future chapters to perform structure-function studies via nonsense 
suppression-based non-canonical amino acid mutagenesis. 
2.2 Introduction 
 The α6 nAChR subunit is primarily localized to the ventral tegmental area and 
substantia nigra pars compacta areas of the brain.1–3  Specifically, α6β2-containing 
subtypes are expressed at the presynaptic terminals of dopaminergic neurons found in the 
mesocorticolimbic and nigrostriatal pathways.4–6  Because they influence the release of 
dopamine from these neurons, α6β2-containing subtypes have been of recent interest, and 
finding agonists that bind specifically to the α6-β2 interface, while avoiding other subtypes, 
is a priority for both addiction and Parkinson’s disease research.7–9 Thus, developing 
detailed maps of the binding site at this interface and how it differs from α4β2 would aid 
in that endeavor.  As Chapter 1 has outlined, structure-function studies using nonsense 
suppression-based non-canonical amino acid mutagenesis is a powerful tool used toward 
this aim.  However, because tRNA is essentially a stoichiometric reagent in the chemical 
acylation technique used in nAChR structure-function studies, protein expression can be 
quite low.  A robust heterologous expression system in Xenopus oocytes is needed for the 
non-suppressed, wild-type nAChR in order to compensate for such a hit once the 
suppression technique is incorporated. 
A heterologous expression system which isolates the α6-β2 binding interface has 
not previously been reported, mainly because α6β2 presents several challenges.10  In the 
brain, the α6 subunit is thought to form α6β2 pentamers, as well as complex subtypes with 
three or more different subunits, such as α6α4β2, α6β2β3, and α6α4β2β3.1  This makes 
studying the pharmacology of α6-containing nAChRs quite challenging in vivo as it is 
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difficult to resolve the roles each subtype contributes.  Furthermore, though α6 and β2 have 
been shown to be translated in Xenopus oocytes, they are unable to form functional 
pentamers, instead forming oligomers that have functional agonist-binding sites but no 
ability to conduct ions.11  In fact, when α6 was first discovered, it was deemed the “orphan 
subunit,” because it could not be functionally expressed in oocytes no matter which other 
subunits were coinjected.  Recent studies have relied on chimeras with an α6 extracellular 
binding domain and an α3 transmembrane domain.12,13  While this strategy yields 
functional expression, it remains unclear what effect the different transmembrane domain 
might have on assembly, and therefore the α6-β2 binding interface.  Others have reported 
developing complex concatemers that have linked as many as five subunits into one 
gene.14,15  While this solution effectively produces pentamers with the desired 
stoichiometry, nonsense suppression in these large single protein chains is likely difficult. 
Rather, the ideal expression system to tolerate nonsense suppression-based non-
canonical amino acid mutagenesis is one that utilizes one or more reporter mutations – 
conventional amino acid substitutions designed to increase translation, transport, or ion 
conductivity without affecting the binding site.  Such a construct must result in a receptor 
that produces large and consistent agonist-induced current traces as well as dose-response 
curves that are monophasic, indicating only a single population of receptors has been 
expressed.  In the work detailed in this chapter, four such reporter mutations were 
introduced into α6β2, and when injected into oocytes produce functional receptors meeting 
all of those requirements. 
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2.2 Reporter Mutations Resulting in Functional Expression of α6β2  
 In order to perform structure-
function studies that probe noncovalent 
interactions between agonists and the α6-β2 
interface, a pure population of α6β2 
receptors must be heterologously expressed 
in Xenopus oocytes.  However, merely 
injecting oocytes with wild-type α6β2 
mRNA does not result in the formation of 
functional ion channels, as applications of 
high doses of acetylcholine (ACh) do not 
result in any current (Figure 1).  In other 
challenging receptors such as α4β2, a mutation made to the ninth residue in the M2 helix, 
which lines the channel pore and whose residues are numbered by a prime notation starting 
from the intracellular end, has resulted in both increased expression and conductance 
without affecting the pharmacological properties of the receptor.16–18  Yet, unlike 
α4L9’Aβ2, when the analogous α6L9’Sβ2 construct is injected into oocytes, no increase in 
current is seen (Figure 1).  Rather, the same result as wild-type α6β2 is achieved in that no 
agonist-induced current is observed at all.   
 Interestingly, α6L9’Sβ4 does show some agonist-induced currents.19  The lack of 
expression observed with α6L9’Sβ2 is therefore likely due to some interesting 
characteristics of the β2 M3-M4 loop, the domain thought to be responsible for trafficking 
from the endoplasmic reticulum (ER) to the cell membrane.  Unlike other beta-like 
Figure 1. The cartoon depicts a schematic of the 
nAChR subunit with circles representing any 
reporter mutations made.  Neither wild-type α6β2 
nor α6L9’Sβ2 produce agonist-induced current.  
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subunits, such as β4, the M3-M4 loop of 
β2 not only lacks an LXM ER exit motif, 
it also has an RRQR ER retention motif.  
Previous studies in mammalian cell line 
showed increased expression of 
fluorescent analogues of α4β2 and α6β2 
by introducing an ER exit motif and 
eliminating the ER retention motif in 
β2.20,21  The mutations 347LFL/LFM349 
and 365RRQR/AAQA368 were therefore 
incorporated into the β2 subunit.  When 
the α6L9’Sβ2LFM/AAQA construct was then 
injected into oocytes, ACh-induced 
currents were observed. 
 The current waveform observed with 
α6L9’Sβ2LFM/AAQA shows a quick spike of 
current upon ACh application followed by 
a smaller but sustained current until the agonist is washed out.  The receptor is possibly 
entering into a desensitized state, but the sustained portion of the trace makes this 
conclusion slightly less certain.  The highly biphasic dose response curve for this construct 
suggests that the unusual looking current trace (an ideal trace would show a square-ish 
wave form with a quick channel opening upon agonist application and sustained activation 
until agonist washout) is due to a mixed population of receptor stoichiometries.  One 
Figure 2.  Shown is an example of the agonist-
induced current trace at α6L9’Sβ2
LFM/AAQA
 
demonstrating an initial current spike and residual 
steady-state until wash out.  The mutations made are 
shown in the cartoon schematic, and results of dose 
response experiments (N = 27) are shown above, fit 
to the biphasic Hill equation: 
 I
norm
=n*(1/(1+EC50
1
)
nH1
) + (1-n)*(1/(1+EC50
2
)
nH2
) 
with each component having its own EC
50
 and Hill 
coefficient.   
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stoichiometry perhaps experiences quick desensitization while another experiences a 
sustained activation until wash out, and the observed trace is a composite of both.  However 
these possible stoichiometries were unable to be resolved by manipulating the mRNA 
injection ratio of α6 to β2.  Furthermore, neither the traces nor the dose response curves 
showed much consistency from cell to cell, with large variances in EC501 and EC502 
observed from curve to curve (as shown by the relatively large error bars and low Hill 
coefficients in Figure 2).  Finally, the average maximum current from these dose response 
experiments was only 0.25 μA, which along with other inconsistencies makes 
α6L9’Sβ2LFM/AAQA unconducive for nonsense suppression. 
 An additional L9’S mutation was made in the β2 subunit in an attempt to further 
increase expression.  The resulting α6L9’Sβ2L9’SLFM/AAQA (abbreviated as α6β2‡ 
throughout the rest of this thesis) showed currents consistently greater than 1 μA in 
Figure 3.  Shown is a representative current trace produced from application of ACh on cells injected 
with α6L9’Sβ2L9’S
LFM/AAQA
 (α6β2
‡
) as well as a schematic picturing each mutation’s location.  The 
results of dose response experiments (N=16) show a monophasic curve that suggests only one population 
of nAChRs is being expressed.   
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response to ACh.  Additionally the waveforms had an ideal square shape that were typical 
from cell to cell (Figure 3).  Dose response experiments produced a monophasic dose 
response curve with little variance in EC50 from cell to cell.  Previous studies on the muscle-
type receptor had shown baseline leak currents to be prohibitively high when all five 
subunits had an L9’S mutation, but the α6β2‡ construct typically produced baseline leak 
currents far less than agonist-induced current.   
2.3 Characterization of α6β2‡ 
2.3.1 Stoichiometry Control of α6β2‡ 
Initial experiments with the α6β2‡ construct suggest the receptor can tolerate 
nonsense suppression, but before any structure-function studies are performed, the receptor 
must be fully optimized and characterized.  As part of that process, the mRNA injection 
ratio of α6 to β2 was varied from 50:1 to 1:20 while keeping the total amount of mRNA 
constant at 10 ng injected per cell.  Two phenotypes were observed based on which subunit 
was biased.  An α6-biased population that 
included mRNA ratios from 50:1 to 1:2 
(α6:β2) had an EC50 around 0.11 μM and 
a Hill coefficient greater than 1.  A second 
phenotype was observed in the three most 
β2- biased injection ratios with an EC50 
around 0.5 μM and a Hill coefficient less 
than 1.  A general attenuation in Figure 4. Results from dose response experiments 
performed at different mRNA α6:β2 ratio injections.  
Note that the α6-biased population’s curves are 
concise with a steep Hill coefficient, whereas the 
more β2-biased curves are spread out and have a low 
Hill coefficient.   
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maximum currents was also observed in the β2-biased population, though this trend is 
difficult to quantify because of oocyte variability. 
The different phenotypes observed likely result from a difference in subunit 
stoichiometries correlated to the ratio of α6 to β2 mRNA injected into cells.  In cases where 
more α6 mRNA is injected relative to β2, more α6 subunits will be translated and pentamers 
are more likely to have a majority α6.  The reverse could be true for the β2 biased scenarios; 
however, while the tight distribution of EC50 values and Hill coefficients suggest a single 
stoichiometry is activated in the α6-biased case, high variance in EC50 values and low Hill 
coefficients suggest the β2-biased ratios present a mixed population of stoichiometries at 
the cell surface.  Previous studies of α4L9’Aβ2 receptors have shown that they are able to 
adopt two different stoichiometries, confirmed to be (α4)2(β2)3 and (α4)3(β2)2.22,23  As with 
α6β2‡, the α4L9’Aβ2 stoichiometry expressed can be influenced by the mRNA injection 
ration, but more work is needed to confirm the exact make-up of the two populations 
observed in α6β2‡.  Because the α6-biased population is better behaved, a high α6 to β2 
Table 1.  Varying mRNA α6:β2 Injection Ratios 
Ratio EC50 (uM) nH Imax (μA) N 
50:1 0.097 ± 0.002 1.17 ± 0.03 8.25 - 57.3 11 
20:1 0.139 ± 0.003 1.64 ± 0.05 0.25 - 1.44 15 
10:1 0.119 ± 0.004 1.17 ± 0.04 4.85 - 70.7 16 
5:1 0.094 ± 0.003 1.17 ± 0.04 0.7 - 79.9 18 
2:1 0.109 ± 0.002 1.14 ± 0.03 0.94 - 79.5 11 
1:1 0.15 ± 0.01 1.15 ± 0.06 4.42 - 14.18 10 
1:2 0.125 ± 0.003 1.23 ± 0.05 3.06 - 31.7 11 
1:5 0.35 ± 0.02 0.095 ± 0.04 0.7 - 8.21 13 
1:10 0.8 ± 0.04 0.83 ± 0.02 1.01 - 4.67 16 
1:20 0.52 ± 0.03 0.86 ± 0.03 1.01 - 10.9 11 
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injection ratio will be used in the characterization studies in the following section as well 
as in the binding studies presented throughout this thesis. 
2.3.2 Pharmacology of α6β2‡ 
 In order to better understand how this new construct behaves compared to other 
subtypes, and to get an idea of what compounds would be interesting to use in structure-
function studies, a panel of agonists was screened at α6β2‡.  Several known nAChR 
agonists – ACh, nicotine, metanicotine, nornicotine, varenicline, cytisine, choline, 
carbamylcholine, and epibatidine – were evaluated in addition to TC299423, an emerging 
candidate for the treatment of nAChR-related disorders and thought to be potentially α6-
selective.24  Dose response experiments were performed for each agonist to determine the 
EC50 and Hill coefficient.  As shown in Table 2, metanicotine, nornicotine, choline, and 
carbamylcholine have higher EC50 values – and are thus less potent – than ACh.  Nicotine, 
varenicline, cytisine, and TC29423 are slightly more potent, while epibatidine has an 
observed EC50 several orders of magnitude lower than ACh.  These trends are consistent 
Table 2. Results of Dose Response and Efficacy Experiments with a Panel of nAChR Agonists at α6β2
‡
 
 Agonist EC50 (µM) nH Imax (µA) N EC50 Eff Attenuation N Eff 
ACh 0.17 ± 0.00 1.36 ± 0.03 0.28 - 14.87 12        
CCh 1.36 ± 0.05 1.12 ± 0.04 3.63 - 52.45 13 0.87 ± 0.04 0.98 ± 0.04 18 
Ch 159 ± 7 1.32 ± 0.05 2.08 - 15.41 14 0.33 ± 0.02 1.06 ± 0.03 15 
Var 0.031 ± 0.003 1.08 ± 0.08 0.51 - 12.07 15 0.33 ± 0.02 0.94 ± 0.02 19 
TC299 0.071 ± 0.003 0.99 ± 0.04 1.73 - 21.86 12 0.59 ± 0.04 0.81 ± 0.05 16 
Nic 0.057 ± 0.002 1.38 ± 0.05 9.48 - 54.42 10 0.49 ± 0.03 0.93 ± 0.02 22 
MetaNic 0.74 ± 0.02 0.98 ± 0.03 0.43 - 40.38 13 0.64 ± 0.04 0.90 ± 0.03 15 
NorNic 0.51 ± 0.01 1.32 ± 0.03 0.31 - 2.36 11 0.72 ± 0.02 0.84 ± 0.04 15 
Cyt 0.027 ± 0.001 1.31 ± 0.05 0.57 - 31.91 11 0.28 ± 0.01 0.97 ± 0.02 20 
Epi 0.00035 ± 0.00003 1.9 ± 0.2 0.47 - 2.81 12 0.54 ± 0.02 0.94 ± 0.04 19 
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with previously reported data using (α6/α3)β2 chimeric constructs where nicotine was 
found to be more potent than ACh.   
 Efficacy tests were also conducted at α6β2‡ with the same panel of agonists.  In this 
experiment, ACh is applied to cells, followed by the agonist of interest and a second dose 
of ACh.  The concentration used for each agonist corresponded to the one that achieves a 
maximum response on the dose response curve.  The current elicited from the agonist dose 
was divided by the initial ACh current to determine efficacy, while the second ACh current 
Figure 5. Top: chemical structures of all the agonists screened at α6β2
‡
 in this chapter.  Bottom: 
a bar graph showing the relative efficacies of each agonist to acetylcholine (in blue), as well as 
the level of attenuation each agonist has on the second dose of acetylcholine (in red). 
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was divided to determine the attenuation level (results shown in Figure 6).  The agonists 
screened were partial agonists, as they all induced a channel response but had efficacy 
values less than 1.  Only TC299423 and nornicotine showed any meaningful levels of 
attenuation at 0.81 and 0.79 respectively. 
2.4 Conclusions 
 All together, these results show that α6β2 nAChRs can be expressed as a controlled 
and pure population in the form of α6β2‡, with consistently large agonist-induced currents 
elicited from ACh as well as a broad panel of compounds.  The results presented in this 
chapter show that α6β2‡ is a good candidate for nonsense suppression-based non-canonical 
amino acid mutagenesis.  The next two chapters will discuss structure-function studies 
using the α6β2‡ construct that probe functional binding interactions made by ACh, nicotine, 
and TC299423 at the α6-β2 interface in order to distinguish this binding site from α4β2.  
Still, more work can be done to further characterize α6β2‡.  Single-channel patch clamp 
recording and analysis of the receptor would be particularly informative and reveal 
information about the gating and kinetics of α6β2 in addition to binding.  Experiments to 
determine the actual stoichiometry of the α6-biased injection ratio population would also 
be useful. 
The α6β2 nAChR subtype has emerged as an important target in the study of 
addiction and Parkinson’s disease, but research has been challenging because of the lack 
of a method for interrogating a pure population of α6β2 receptors.  The α6β2‡ construct 
has been shown here to be an excellent heterologous expression system in Xenopus oocytes 
and a useful tool for comparing agonists amongst each other.  Furthermore, it has opened 
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avenues for more complex studies that will hopefully one day help inform toward the 
design of subtype-specific drugs. 
2.5 Materials and Methods 
Molecular Biology 
Rat α6 and β2 nAChRs were in the pGEMhe vector, a cDNA plasmid optimized for protein 
expression in Xenopus oocytes.  Site-directed mutagenesis was performed by PCR using 
the Stratagene QuikChange protocol and primers ordered from Integrated DNA 
Technologies (Coralville, IA).  Circular cDNA was linearized with SbfI (New England 
Biolabs, Ibswich, MA) and then transcribed in vitro using T7 mMessage mMachine kit 
(Life Technologies, Santa Clara, CA), with a purification step after each process (Qiagen, 
Valencia, CA).  Final concentrations were quantified by UV spectroscopy. 
Ion Channel Expression 
Xenopus laevis oocytes (stage V to VI) were sourced from both a Caltech facility and 
Ecocyte Bio Science (Austin, TX).  Oocytes were injected with 50 nL solution containing 
either 5 or 10 ng mRNA.  The α6:β2 ratio is presented as a mass ratio.  Cells were incubated 
24-48 hours at 18oC in ND96 solution (96 mM NaCl, 2mM KCl, 1 mM MgCl2, and 5mM 
HEPES, pH 7.5) enriched with theophylline, sodium pyruvate, gentamycine, and horse 
serum. 
Whole-Cell Electrophysiological Characterization 
Acetylcholine chloride, choline chloride, carbamylcholine chloride, cytisine, and (-)-
nicotine tartrate were purchased from Sigma Aldrich (St Louis, MO), (±)-epibatidine was 
purchased from Tocris (Bristol, UK), (S)-nornicotine hydrochloride was purchased from 
Matrix Scientific (Columbia, SC), while varenicline (Pfizer) and metanicotine and 
TC299423 (Targacept) were generous gifts.  Agonist-induced currents were recorded in 
TEVC mode using the OpusXpress 6000A (Molecular Devices, Sunnyvale, CA) at a 
holding potential of -60 mV in a running buffer of Ca2+-free ND96.  Agonists were 
prepared in Ca2+-free ND96 and delivered to cells via a 1 mL application over 15 sec 
followed by a 2 min wash.  Data from dose-response experiments were normalized, 
averaged, and fit to the Hill equation using Kaleidagraph (Synergy Software, Reading PA), 
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though data are visualized here with Prism (GraphPad Software, La Jolla, CA).  Error bars 
are presented as standard error of the mean, while EC50 and Hill coefficient errors are 
reported by Kaleidagraph and represent the sum of the squared error between the data and 
the calculated fit.  
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Chapter 3: Probing for Agonist Cation-π Interactions  
in α6β2 nAChRs† 
3.1 Abstract 
 A major goal of the work presented in this thesis is to characterize the binding site 
of the α6β2 nAChR subtype in an attempt to differentiate it from the other subtypes.  With 
the α6β2‡ construct presented in Chapter 2, this is now possible.  Previous studies with the 
α4β2 subtype have shown that acetylcholine and nicotine form a critical cation-π 
interaction with a conserved tryptophan on loop B, while studies in the α7 subtype show a 
functional cation-π interaction is made between acetylcholine and a tyrosine on loop A.  
This chapter investigates whether acetylcholine, nicotine, and TC299423 make a functional 
cation-π interaction at TrpB, TyrA, and TyrC2 using structure-function studies where the 
aromatic side chain is replaced with analogues containing electron-withdrawing 
substitutions on the ring system.  When a functional cation-π interaction is present, as 
negative electrostatic potential is drawn away from the center of the aromatic ring, binding 
should decrease.  Therefore, a progressive increase in EC50 over the course of a fluorination 
series indicates a functional cation-π interaction.  Of the nine interactions probed, only 
acetylcholine at TrpB was observed to have such a trend.  This suggests α6β2 has a unique 
binding site from the other subtypes, and raises important questions about the relevant 
binding interactions occurring when nicotine and TC299423 activate the receptor. 
                                                 
† A portion of the work presented in this chapter is adapted, with permission, from: 
Post, M. R., Limapichat, W., Lester, H. A. & Dougherty, D. A. Heterologous expression and nonsense 
suppression provide insights into agonist behavior at α6β2 nicotinic acetylcholine receptors. 
Neuropharmacology 97, 376-382 (2015). doi:10.1016/j.neuropharm.2015.04.009  
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3.2 Introduction 
The α6β2‡ construct discussed in Chapter 2 opens the door to studies that probe for 
binding interactions at the α6-β2 interface.  Throughout the nAChR family, a binding site 
forms at the interface of alpha and beta-like subunits in their extracellular domains – where 
α forms the primary face and contributes loops A-C and β forms the complementary face 
and contributes loops D-F –  and is shaped by a cluster of aromatic residues.1,2  This so-
Figure 1. Above is a snapshot of the aromatic box region in AChB, crystalized with HEPES.  The 
primary face is colored blue while the complementary face is tan, and the five aromatic residues that 
make up the box are highlighted in green.  Below is an alignment of the human alpha subunits that can 
contribute to the primary face of the binding site as well as the subunits that can contribute loop D to the 
complementary face. PDB: 1I9B 
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called aromatic box is formed by four of 
the six loops contributing five aromatic 
side chains – TyrA (α6:Y93), TrpB 
(α6:W149), TyrC1 (α6:Y190), TyrC2 
(α6Y197), and TrpD (β2:W57) – and is 
responsible for binding the cationic moiety 
of agonists and antagonists.3  The aromatic 
box has been visualized via structures of 
the acetylcholine binding protein 
(AChBP), a water soluble protein 
homologous to the extracellular region 
(Figure 1) and shows agonists positioned 
such that the cationic moiety is pointing 
toward the face of TrpB.1  The nature of the aromatic box suggests, then, that a cation-π 
interaction contributes significantly to ligand binding. 
The cation-π interaction is an electrostatic interaction between a positively charged 
moiety – such as quaternary ammonium group of ACh – and the negative electrostatic 
potential concentrated on the face of an aromatic group, such as the phenol ring of tyrosine 
or the indole group of tryptophan (Figure 2).4,5  The cation-π interaction has been 
demonstrated in the gas phase, with potassium ions and ammonium binding to benzene 
with about 19 kcal/mol binding energy.6  In addition to its significance to ligand recognition 
in the pLGIC receptor family,7 discussed in depth in Chapter 1, the cation-π interaction has 
been found to be important in general protein structure as well, with an average of one 
Figure 2. A three dimensional view of a cation-π 
interaction between tetramethylammonium and an 
indole ring using electrostatic potential maps 
where red represents negative electrostatic 
potential and blue, positive.  A structural schematic 
below shows a similar cation-π interaction 
between the quaternary ammonium group of 
acetylcholine and an indole ring. 
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energetically significant cation-π interaction observed between a positively charged side 
chain and an aromatic side chain for every 77 residues in a protein.8 
A recent computational study suggests that all five residues in the AChBP aromatic 
box can contribute a cation-π interaction to the agonist, with the TrpB, TyrC2, and TyrA 
side chains contributing 8.3, 8.0, and 2.3 kcal/mol respectively.9  It is likely that this is 
possible at the nAChR aromatic boxes as well; however, only certain residues have 
empirically been found to form a functional cation-π interaction with agonists.7  Previously 
reported structure-function studies with α4β2 and muscle-type have confirmed that a 
cation-π interaction with TrpB is critical for the binding of ACh.10,11  At the α7-α7 interface, 
the map is slightly different, as acetylcholine makes a functionally important cation-π 
interaction with TyrA instead.12  An alignment of four of the six loops (Figure 1) shows 
that all five aromatic residues are conserved amongst α6, α4, and α1, suggesting that a 
cation-π interaction may play a similarly important role at the α6-β2 interface 
Structure-function studies are used to probe for functional noncovalent binding 
interactions, wherein a small perturbation is made to the binding site, and changes in EC50 
are monitored.  For cation-π interactions, this means substituting the aromatic residue with 
a non-canonical amino acid that has less concentrated negative electrostatic potential on 
the face of the ring, accomplished by using analogues with electron-withdrawing 
substituents on the ring’s edge, such as fluorotryptophan and fluorophenylalanine.  The 
effect is additive as well, with additional fluorine substituents causing a greater loss of 
function.  
 38 
 
Figure 3.  A representative schematic of the structure-function studies used to probe for cation-π 
interactions wherein electron-withdrawing substituents incrementally draw negative electrostatic 
potential away from the face of the aromatic ring.  The results from dose response experiments at each 
analogue are then plotted and fit to the Hill equation.  A loss of function (red) causes a rightward shift in 
the dose response curve away from wild-type (blue) and an increase in EC
50
, while a gain of function 
mutation (green) has the opposite effect.  Below are the other non-canonical amino acids used in this 
chapter. 
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Because these mutations affect only the binding site, and gating is not perturbed, 
EC50 values can be used to measure the ligand-binding equilibrium constant for apo and 
bound states.  Thus, the log(EC50) is proportional to the binding energy, and as the binding 
interaction is theoretically weakened, the EC50 is expected to increase in the case of a 
functionally important  cation-π interaction.  The theoretical binding energy between an 
agonist and each analogue in these experiments has traditionally been approximated with 
an ab initio Hartree-Fock calculation between a sodium ion and the side chain.  The 
log(EC50) for each analogue is then plotted against these values and a linear plot with a 
negative slope indicates a functionally important cation-π interaction. 
The work presented in this chapter takes a similar approach with ACh, nicotine, 
and TC299423 at three residues aligned with amino acids previously shown to form a 
functionally important cation-π interaction – TrpB, TyrA, and TyrC2 – in α6β2‡.  An 
updated set of theoretical cation-π binding energy values are used, calculated using M06 
Figure 4. Structures and electrostatic potential maps of the agonists involved in structure-function 
studies, from HF 6-31G** calculations ranging from -10 (red) to +150 (blue) kcal/mol 
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density functional theory instead of Hartree-Fock.‡  Of all nine ligand-residue 
combinations tested, only ACh at TrpB shows a cation-π interaction, suggesting the α6-β2 
interface indeed has a unique pharmacology. 
3.3 Cation-π Binding Studies at TrpB 
3.3.1 Acetylcholine binding at TrpB 
 Acetylcholine has been found to make a functionally important cation-π interaction 
at TrpB with every nAChR subtype investigated except α7.  As such, this was the logical 
starting point to probe the α6-β2 interface.  For initial nonsense suppression experiments, 
α6β2‡ with an α6 W149TAG mutation was injected into oocytes in a 10:1 mRNA ratio 
alongside tRNA acylated with the desired non-canonical tryptophan analogues.  Dose 
response experiments were then performed with ACh, and the EC50 value for each analogue 
was determined.  Considering first the fold-shifts in EC50 for 5-F1Trp, 5,7-F2Trp, and 5,6,7-
F3Trp, there is a clear trend, with each additional fluorine causing greater fold-shifts.  To 
be certain this correlation was due to electrostatic effects, 5-MeTrp, 5-F1Trp, and 5-BrTrp 
– all residues with a single substituent at the 5 position – were examined.  The steric 
demands of these substituents are Br>Me>F, while the calculated cation-π modifying 
ability is F≈Br>Me.  The data follow the cation-π prediction well, and therefore cannot be 
interpreted as a steric effect. 
Figure 5 shows all the data collected at TrpB.  There are some outliers in the 
analysis.  While 5-F1Trp and 6-F1Trp show very similar results and follow the trend 
closely, 4-F1Trp is 3-4 times more potent than expected, producing near wild-type 
                                                 
‡ Calculations were performed by Matthew Davis 
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behavior.  This is the only non-canonical amino acid studied with a substituent in the 4 
positon, suggesting a special interaction at this site.  Also, 5-CNTrp, which is predicted to 
be strongly inactivating, shows the expected loss of function, but the effect is roughly 5-
fold greater than expected.  The cyano group is quite polar in and of itself, and therefore 
could be influencing the binding site in unexpected ways.  Still, when taken as a whole, 
Figure 5. The log of the fold-shift in EC
50
 is plotted against the M06 6-31G** calculated binding energy 
between a sodium ion and each non-canonical side chain used at Trp B in 10:1 α6β2
‡
.  The linear trend 
indicates the presence of a strong cation-π interaction between the indole side chain and ACh. 
Table 1. Investigating a Cation-π Interaction with ACh at 10:1 α6β2
‡
 
10:1 EC50 (uM) nH Imax (uA) Fold Shift N 
Trp 0.169 ± 0.003 1.36 ± 0.03 0.28 - 14.87 1 12 
MeTrp 0.11 ± 0.002 1.18 ± 0.02 0.19 - 19.36 0.7 12 
4-F
1
Trp 0.21 ± 0.006 1.25 ± 0.04 0.71 - 6.92 1.2 9 
5-F
1
Trp 0.81 ± 0.01 1.37 ± 0.03 1.39 - 14.37 4.8 10 
6-F
1
Trp 0.66 ± 0.02 1.30 ± 0.04 0.18 - 4.28 3.9 10 
BrTrp 0.53 ± 0.01 1.32 ± 0.04 0.22 - 15.05 3.1 14 
F
2
Trp 1.41 ± 0.02 1.43 ± 0.02 0.76 - 9.33 8.3 9 
CNTrp 15.1 ± 0.6 1.25 ± 0.05 0.31 - 13.28 89 14 
F
3
Trp 4.5 ± 0.2 1.04 ± 0.03 0.09 - 1.94 27 12 
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these results provide strong evidence that ACh is involved in a functionally important 
cation-π interaction with TrpB at the α6-β2 interface. 
Figure 6. This fluorination plot shows ACh at Trp B at three different α6-biased injection ratios used 
α6β2
‡
.  Both the 20:1 and 50:1 injection ratios fit closely to the 10:1 data shown here and fit with a linear 
trend in Figure 3.  
Table 2. Investigating Cation-π Interactions at TrpB with Varying mRNA Injection Ratios  
20:1 EC50 (uM) nH Imax (uA) Fold Shift N 
Trp 0.17 ± 0.01 1.22 ± 0.05 0.67 - 15.1 1 11 
MeTrp 0.145 ± 0.004 1.35 ± 0.05 0.54 - 3.36 0.9 10 
5-F
1
Trp 1.29 ± 0.04 1.15 ± 0.03 0.48 - 13.68 7.6 10 
6-F
1
Trp 0.73 ± 0.01 1.29 ± 0.02 0.09 - 4.59 4.3 12 
BrTrp 0.64 ± 0.02 1.24 ± 0.03 0.56 - 8.28 3.8 12 
F
2
Trp 1.34 ± 0.03 1.21 ± 0.02 0.08 - 9.08 7.9 10 
F
3
Trp 6.9 ± 0.4 1.03 ± 0.05 0.04 - 0.82 41 11 
  
50:1 EC50 (uM) nH Imax (uA) Fold Shift N 
Trp 0.180 ± 0.004 1.33 ± 0.04 0.14 - 6.17 1. 16 
MeTrp 0.126 ± 0.002 1.29 ± 0.02 0.2 - 6.66 0.7 13 
5-F
1
Trp 0.92 ± 0.02 1.46 ± 0.04 0.05 - 7.74 5.1 12 
6-F
1
Trp 0.58 ± 0.01 1.33 ± 0.04 0.06 - 2.05 3.2 9 
BrTrp 0.69 ± 0.02 1.21 ± 0.04 0.17 - 5.59 3.8 14 
F
2
Trp 1.69 ± 0.07 1.36 ± 0.07 0.11 - 0.66 9.4 10 
F
3
Trp No Response 
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As discussed in Chapter 2, α6β2‡ exhibits an mRNA injection ratio effect, where a 
large increase in EC50 and decrease in Hill coefficient is observed with the more β2-biased 
injection ratios.  Taking this into account, one could argue that the trends presented thus 
far are actually due to a shift in stoichiometry as a result of the hit in translation by α6 as 
the non-canonical amino acid strays further from wild-type.  In order to ensure the results 
were actually due to electrostatics, the same experiments were attempted first using a more 
β2-biased injection ratio.  However, no agonist-induced currents were ever observed, 
suggesting functional channels were unable to form.  Instead, injection ratios were pushed 
further into the α6-biased direction, with the same analogue progression (except 4-F1 and 
5-CN) tested at 20:1 and 50:1 α6:β2 ratios.  As shown in Figure 6, these results closely 
track those already presented at the 10:1 ratio.  In all three cases, the fluorination plots have 
linear fits, and the Hill coefficients for each dose response curve remains greater than 1.  
These data confidently assert that each nonsense-suppression experiment has evaluated the 
same stoichiometry, and that the structure-function studies indeed prove a cation-π 
interaction between ACh and TrpB. 
3.3.2 Nicotine and TC299423 binding at TrpB 
 The same strategy described above was used to probe whether nicotine and 
TC299423 form functionally important cation-π interactions with TrpB (Figure 7).  For 
nicotine, the 5-F1Trp and 5-BrTrp show the expected shifts in EC50 based on the trend 
observed with ACh.  However, the F2Trp and F3Trp EC50 values are not meaningfully 
different from the monosubstituted analogues.  This rules out a strong cation-π interaction 
between nicotine and TrpB.  A more complicated result is seen with TC299423, with the 
monosubstituted analogues again following the trend established by ACh, but overall the 
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results do not show a linear trend and therefore do not support the presence of a strong 
cation-π interaction.  These are the exact same side chain mutations that were employed in 
the ACh experiments and produced a clear linear response.  Thus, the receptor is able to 
tolerate these modest changes to structure, and while a weak interaction between these 
Figure 7. Nicotine (Nic) and TC299423 were also probed for a cation-π interaction with Trp B, 
however unlike ACh, neither of these agonists form a linear trend and therefore do not form a strong 
cation-π interaction 
Table 3.  Investigating Cation-π Interactions with Nicotine and TC299423 at TrpB 
Nic EC50 (uM) nH Imax (uA) Fold Shift N 
Trp 0.15 ± 0.006 1.43 ± 0.06 0.09 - 5.8 1 12 
MeTrp 0.094 ± 0.003 1.36 ± 0.05 0.31 - 3.95 0.6 11 
F
1
Trp 0.75 ± 0.02 1.39 ± 0.06 0.07 - 2.06 5.0 12 
BrTrp 0.98 ± 0.03 1.42 ± 0.04 0.08 - 5.65 6.5 14 
F
2
Trp 0.78 ± 0.04 1.3 ± 0.06 0.32 - 2.13 5.2 10 
F
3
Trp 0.89 ± 0.02 1.28 ± 0.03 0.05 - 1.05 5.9 10 
                        
TC299423 EC50 (uM) nH Imax (uA) Fold Shift N 
Trp 0.093 ± 0.004 1.09 ± 0.04 0.33 - 3.78 1 11 
MeTrp 0.073 ± 0.004 0.92 ± 0.03 0.15 - 2.35 0.9 13 
F
1
Trp 0.22 ± 0.01 1.01 ± 0.04 0.27 - 3.49 2.4 15 
BrTrp 0.25 ± 0.008 1.01 ± 0.03 0.1 - 7.71 2.7 11 
F
2
Trp 0.138 ± 0.006 0.98 ± 0.04 0.06 - 1.87 1.5 11 
F
3
Trp 0.63 ± 0.03 0.90 ± 0.03 0.05 - 0.28 6.8 13 
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agonists and TrpB cannot be ruled out, the hallmark cation-π interaction observed in many 
pLGICs, including nicotine at the α4-β2 interface, is clearly absent. 
 While α6β2 is more similar to α4β2, in that both subtypes are neuronal and share 
the β2 subunit, the pharmacology at α6β2‡ is actually more reminiscent of the α1β1γδ 
muscle-type nAChR.  In this subtype, ACh makes a cation-π interaction with TrpB, but 
nicotine does not.13  The difference between muscle-type and α4β2 subtypes was explained 
by the residue at the i + 4 position relatve to TrpB; a lysine in the α4 subunit and a glycine 
in α1.  This residue, when glycine, reshapes the binding site preventing nicotine from 
coming into close contact with TrpB.10  However, in α6, the i + 4 residue from TrpB is also 
a lysine, suggesting the lack of a cation-π interaction with nicotine is due to another issue.  
It is also important to note that both agonists are quite efficacious at α6β2‡, and that while 
nicotine is not very potent at muscle-type, in α6β2‡ it has a lower EC50 than ACh, further 
highlighting the unique nature of α6β2-containing receptors. 
3.4 Cation-π Binding Studies at Tyrosines 
3.4.1 Cation-π Binding Studies at TyrC2 
 TyrC2 is capable of forming a functionally important cation-π interaction with 
epibatidine at the α7-α7 interface as well as secondary amine agonists at α4β2, as will be 
shown in Chapter 5.  Thus, it seemed pertinent to probe this interaction at the α6-β2 
interface, especially with the previous results suggesting nicotine and TC299423 do not 
make cation-π interactions with TrpB.  The strategy for probing a tyrosine cation-π 
interaction is largely the same as a tryptophan with one major adjustment.  Adding electron-
withdrawing groups to a tyrosine phenol ring would adversely affect the pKa of the 
hydroxyl group.  Because of this, it would be impossible to gauge whether changes in EC50 
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observed from fluorinating tyrosine were due to changes in electrostatics or the increased 
acidity of the phenol.  Therefore, tyrosine is first substituted with phenylalanine and then 
Figure 8.  Results from structure-function studies probing for cation-π interactions at TyrC2.  Every 
fluorinated phenylalanine had an EC
50
 similar to wild-type suggesting no functionally important cation-π 
interactions are made with this amino acid 
 Table 4.  Investigating Cation-π Interactions at TyrC2  
ACh EC50 (uM) nH Imax (uA) Fold Shift N 
Phe 1.07 ± 0.03 1.2 ± 0.03 0.19 - 11.79 1.0 13 
F
1
Phe 1.2 ± 0.03 1.24 ± 0.03 0.13 - 5.52 1.1 13 
F
2
Phe 1.14 ± 0.03 1.38 ± 0.04 0.29 - 9.23 1.1 8 
F
3
Phe 0.95 ± 0.03 1.45 ± 0.05 5.09 - 15.47 0.9 5 
                        
Nic EC50 (uM) nH Imax (uA) Fold Shift N 
Phe 1.01 ± 0.04 1.23 ± 0.04 0.14 - 3.41 1.0 14 
F
1
Phe 0.74 ± 0.02 1.53 ± 0.06 0.28 - 1.89 0.7 13 
F
2
Phe 0.81 ± 0.02 1.46 ± 0.06 0.41 - 5.32 0.8 6 
F
3
Phe 0.61 ± 0.04 0.91 ± 0.04 4.26 - 20.11 0.6 7 
                        
TC299423 EC50 (uM) nH Imax (uA) Fold Shift N 
Phe 0.68 ± 0.02 0.88 ± 0.02 0.08 - 3.87 1.0 11 
F
1
Phe 0.7 ± 0.04 0.92 ± 0.04 0.09 - 3.29 1.0 12 
F
2
Phe 0.88 ± 0.1 0.96 ± 0.08 0.10 - 4.00 1.3 5 
F
3
Phe 0.9 ± 0.08 1.2 ± 0.1 1.88 - 5.69 1.3 3 
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fluorinated, with quantitative fold-shifts in EC50 using phenylalanine as the reference. 
 In α6β2‡, the α6 cDNA TyrA codon was mutated to TAG and dose response 
experiments were performed with Phe, 4-F1Phe, 3,5-F2Phe, and 3,4,5-F3Phe.  While the 
initial Tyr to Phe mutation results in roughly a 7-fold loss of function, none of the 
fluorinated analogues show any meaningful changes in EC50 compared to Phe.  It should 
be noted that nonsense suppression proved to be immensely challenging at this site, and 
the number of replicates are therefore lower than usually desired.  However, the current 
wave-forms and dose response curves of successful attempts do not look unusual, and there 
is little reason to be skeptical of the results that none of the agonists make a cation-π 
interaction with α6 YC2. 
3.4.2 Cation-π binding studies at TyrA 
 The α7-α7 interface has also shown that TyrA is can make a functionally important 
cation-π interaction with ACh; however, no agonist studied has made a cation-π interaction 
with α4β2 TyrA.  In α6β2‡, the fluorination series yields some interesting results.  The 
initial Tyr to Phe mutation causes a one hundred-fold shift in EC50.  This enormous loss of 
function suggests the tyrosine phenol group makes a critical interaction with either the 
agonist (which is unlikely) or another amino acid.  This theory is supported by the recovery 
in binding (a 2 to 10 fold-shift gain of function relative to Phe) that occurs when a fluorine 
atom is substituted in the 4 position, as seen in 4-F1Phe and 3,4,5-F3Phe.  The 3,5-F2Phe 
substitutions show varying results, with a 5-fold gain of function relative to Phe with ACh, 
and near-Phe EC50 values for nicotine and TC299423.  Overall, these data suggest that 
TyrA plays an important role in α6β2 function, but that role likely does not involve making 
a cation-π with the agonist. 
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Figure 9. Results from structure-function studies probing for cation-π interactions at TyrA show 
interesting results that suggest the 4 position of the phenyl ring is important for receptor function, but that 
a functionally important cation-π interaction with these agonists is not present. 
Table 5. Investigating Cation-π Interactions at TyrA 
ACh EC50 (uM) nH Imax (uA) Fold Shift N 
Phe 15.0 ± 0.7 1.28 ± 0.06 0.09 - 14.40 1.0 13 
F
1
Phe 8.3 ± 0.4 1.24 ± 0.07 0.13 - 2.19 0.6 12 
F
2
Phe 2.61 ± 0.08 1.35 ± 0.05 0.23 - 1.29 0.2 13 
F
3
Phe 3.31 ± 0.09 1.07 ± 0.03 0.04 - 2.77 0.2 12 
                        
Nic EC50 (uM) nH Imax (uA) Fold Shift N 
Phe 1.39 ± 0.07 1.07 ± 0.04 0.07 - 3.98 1.0 11 
F
1
Phe 0.20 ± 0.01 1.35 ± 0.07 0.06 - 2.00 0.1 10 
F
2
Phe 1.9 ± 0.1 1.24 ± 0.06 0.10 - 0.75 1.4 10 
F
3
Phe 0.18 ± 0.01 1.4 ± 0.1 0.09 - 1.05 0.1 10 
                        
TC299423 EC50 (uM) nH Imax (uA) Fold Shift N 
Phe 6.5 ± 0.7 1.2 ± 0.1 0.04 - 0.14 1.0 9 
F
1
Phe 1.56 ± 0.04 1.06 ± 0.03 0.21 - 1.41 0.2 10 
F
2
Phe 4.9 ± 0.3 1.18 ± 0.07 0.05 - 0.28 0.8 13 
F
3
Phe 3.95 ± 0.4 1.01 ± 0.07 0.01 - 1.11 0.6 10 
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3.4 Conclusion 
 Testing ACh, nicotine, and TC299423 at three different aromatic residues at the 
α6-β2 interface – TrpB, TyrA, and TyrC2 – has yielded nine different fluorination series. 
Yet, only one of these plots supports a cation-π interaction: ACh with TrpB.  That only one 
of these interactions is functionally important is quite surprising.  Of the 22 TrpB-agonist 
combinations tested in a pLGIC, 18 produced linear fluorination plots.7  This suggests that 
the binding site of α6β2 has a unique pharmacology.  TyrC1 was the last residue where 
nonsense suppression was attempted, but the technique proved unable to work at this site.  
Future work should investigate what specific role the TyrA and TyrC2, as well as if TrpD 
contributes any meaningful interactions.  The next chapter will investigate the role 
hydrogen bonding has on agonist binding and will answer some, but not all of the questions 
raised here. 
3.6 Materials and Methods 
Molecular Biology 
Rat α6L9’S and β2L9’SLFM/AAQA nAChRs were in the pGEMhe vector, a cDNA plasmid 
optimized for protein expression in Xenopus oocytes.  Site-directed mutagenesis was 
performed by PCR using the Stratagene QuikChange protocol and primers ordered from 
Integrated DNA Technologies (Coralville, IA).  Circular cDNA was linearized with SbfI 
(New England Biolabs, Ibswich, MA) and then transcribed in vitro using T7 mMessage 
mMachine kit (Life Technologies, Santa Clara, CA), with a purification step after each 
process (Qiagen, Valencia, CA).  Final concentrations were quantified by UV 
spectroscopy. 
Ion Channel Expression 
Xenopus laevis oocytes (stage V to VI) were sourced from both a Caltech facility and 
Ecocyte Bio Science (Austin, TX).  Oocytes were injected with 50 nL solution containing 
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either 5 or 10 ng mRNA.  The α6:β2 ratio is presented as a mass ratio.  Cells were incubated 
24-48 hours at 18oC in ND96 solution (96 mM NaCl, 2mM KCl, 1 mM MgCl2, and 5mM 
HEPES, pH 7.5) enriched with theophylline, sodium pyruvate, gentamycine, and horse 
serum. 
Non-canonical Amino Acid Incorporation 
The cyanomethylester form of NVOC-protected tryptophan and phenylalanine analogues 
was coupled to dinucleotide dCA and enzymatically ligated to UAG-suppressor 74-mer 
THG73 tRNACUA as previously described.14  The product was verified by MALDI time-of-
flight mass spectrometry on a 3-hydroxypicolinic acid matrix.  The non-canonical amino 
acid-coupled tRNA was deprotected by photolysis on a 500 W Hg/Xe arc lamp, filtered 
with Schott WG-320 and UG-11 filters, immediately prior to coinjection with mRNA 
containing the UAG mutation at the site of interest.  mRNA and tRNA were typically 
injected in a 1:1 or 1:2 volume ratio in a total volume of 50 or 75 nL respectively so that 
25 ng of mRNA was injected per cell.  In cases where observed agonist-induced currents 
were low after 48 hour incubation – likely due to low receptor protein expression – a second 
injection of mRNA and tRNA was performed after 24 hours.  The fidelity of non-canonical 
amino acid incorporation was confirmed at Trp with a wild-type recovery experiment 
where tryptophan was loaded onto tRNA.  If this experiment yielded similar to EC50 to 
wild-type then the cell incorporated the charged residue and nothing else.  This was 
accomplished with the Tyr sites by comparing tRNA charged with Phe to a conventional 
Y-Phe mutation.  A read-through/reaminoacylation test served a negative control by 
injecting unacylated full-length 76-mer tRNA.  Lack of current proved no detectable 
reaminoacylation at the TrpB site. 
Whole-Cell Electrophysiological Characterization 
Acetylcholine chloride and (-)-nicotine tartrate were purchased from Sigma Aldrich (St 
Louis, MO), while TC299423 (Targacept) was a generous gift.  Agonist-induced currents 
were recorded in TEVC mode using the OpusXpress 6000A (Molecular Devices, 
Sunnyvale, CA) at a holding potential of -60 mV in a running buffer of Ca2+-free ND96.  
Agonists were prepared in Ca2+-free ND96 and delivered to cells via a 1 mL application 
over 15 sec followed by a 2 min wash.  Data from dose-response experiments were 
normalized, averaged, and fit to the Hill equation using Kaleidagraph (Synergy Software, 
Reading PA), though data are visualized here with Prism (GraphPad Software, La Jolla, 
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CA).  Error bars are presented as standard error of the mean, while EC50 and Hill coefficient 
errors are reported by Kaleidagraph and represent the sum of the squared error between the 
data and the calculated fit. 
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Chapter 4: Probing for Agonist Hydrogen Bonds in α6β2 
4.1 Abstract 
 Designing agonists that are selective for specific subtypes of the nicotinic 
acetylcholine receptor is a major goal in nicotine addiction research.  Intricate knowledge 
of how agonists bind at the α6-β2 interface, as well as how this binding site differs from 
other neuronal subtypes such as α4β2, is therefore important.  The previous chapter showed 
acetylcholine makes a functionally important cation-π interaction with Trp149, but nicotine 
and TC299423 do not.  Furthermore, no cation-π interactions were observed at TyrC2 or 
TyrA with any of the agonists.  The cation-π interaction at TrpB is one that has been 
observed in a majority of the agonists investigated in neuronal nAChR subtypes, and 
therefore a different mode of binding for these two is likely in α6β2.  Chapter 4 explores 
the role of hydrogen binding between the cationic amine moiety of agonists and the 
backbone carbonyl associated with TrpB.  Probing this interaction is accomplished by 
substituting the i + 1 residue, Thr150, to threonine α-hydroxy acid (Tah). This mutates the 
backbone amide bond to an ester bond, thereby attenuating the carbonyl’s hydrogen bond 
accepting ability.  With the α6β2‡ T150Tah mutant, nicotine shows a 24-fold loss of 
function, TC299423 shows a modest loss, and acetylcholine shows no effect.  The effect 
at nicotine was further analyzed via a double-mutant cycle analysis wherein N’-
methylnicotinium was utilized as the second “mutant”.  In α6β2‡, the double-mutant 
demonstrates a loss of function that is non-additive with an Ω value of 88 and a ΔΔG of -
2.6 kcal/mol.  This suggests that nicotine makes a strong enough hydrogen bond with the 
TrpB backbone carbonyl to explain why a cation-π interaction was not previously observed 
there; however, the picture for TC299423 remains murky. 
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4.2 Introduction 
 Previous work, discussed in detail in Chapter 3, has shown that at the α6-β2 
interface, while ACh makes a functionally important cation-π interaction, nicotine and 
TC299423 do not.1  This binding mode differs greatly from the α4β2 subtype, and 
specifically the α4-β2 interface, which has been studied in depth with structure-function 
studies over the last several years.2  Those studies revealed three key binding interactions: 
the canonical cation-π interaction with α4 TrpB, a hydrogen bond with the backbone 
carbonyl associated with TrpB, and an additional hydrogen bond between nicotine’s 
pyridine nitrogen and a backbone NH on loop E of the β2 subunit. 
 This chapter investigates the role of that second interaction in α6β2, the hydrogen 
bond between an agonist’s amine moiety and the backbone carbonyl associated with TrpB.  
While quaternary amine agonists such as acetylcholine are unable to make a hydrogen 
bond, such interactions have been observed in both stoichiometries of α4β2 for nicotine, 
varenicline, and cytisine.3,4  Nicotine also shows a strong hydrogen bond interaction in 
α4β4, but not at the muscle-type.5,6  In each of those instances, evidence of the hydrogen 
bond was accompanied by a linear fluorination plot at TrpB; however, because nicotine 
did not show evidence of making a strong cation-π interaction at TrpB with α6β2‡, it was 
not necessarily obvious if it could make the hydrogen bond at this residue in that subtype.  
This chapter will describe how structure-function studies using an α-hydroxy acid 
substitution reveal that nicotine indeed makes a functional hydrogen bond with this 
backbone carbonyl at the α6-β2 interface.  The interaction will be further supported and 
quantified by a double mutant cycle analysis utilizing N’-methylnicotinium. 
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4.3 Probing for Hydrogen Bonds in α6β2 at the TrpB Carbonyl 
4.3.1 The α-hydroxy acid Strategy 
 To probe for hydrogen bonds between an agonist and the nAChR protein backbone, 
nonsense suppression-based, site specific, non-canonical amino acid mutagenesis is once 
again employed.  In this structure-function study, the hydrogen bond accepting ability of 
the backbone carbonyl is attenuated by making a mutation one amino acid downstream 
from the residue of interest, i.e. at the i +1 residue to TrpB.   Due to the loss of resonance 
when the nitrogen is replaced with an oxygen, an ester carbonyl is a weaker hydrogen bond 
acceptor.7  An amide-to-ester mutation of this type is achieved not through an amino acid, 
but an α-hydroxy acid substitution at the i + 1 residue from the carbonyl of interest (Figure 
1).8  Remarkably, the Xenopus oocyte ribosome accepts the Tah-bound tRNA and inserts 
the hydroxy acid into the nascent strand as though it were an amino acid and continues 
translation as per usual leading to functional receptors at the cell surface. 
If the agonist is indeed making a functionally important hydrogen bond with the 
backbone in this location, an amide-to-ester backbone mutation would weaken this 
interaction.  Therefore, an increase in EC50 upon mutation to the α-hydroxy acid confirms 
the presence of a functionally important hydrogen bond.  This strategy will be applied at 
α6β2‡ with ACh, nicotine, and TC299423 in an attempt to further clarify some of the 
surprising results seen in Chapter 3.  If nicotine and TC299423 show strong hydrogen 
bonding interactions, it might explain the lack of cation-π interactions observed in the 
previous chapter and further develop the binding map at the α6-β2 interface. 
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Figure 1.  The Thr to Tah mutation shown at the top leads to an amide-to-ester backbone mutation in the 
protein.  This mutation has the effect of attenuating the hydrogen bonding ability of the carbonyl one amino 
acid up from the site of mutation.  In this case, a T150Tah mutation causes attenuation in the hydrogen 
bond accepting ability of the carbonyl associated with TrpB (Trp149) that leads to an increase in EC
50
 as 
shown with nicotine (Nic) in the dose response curves at the bottom. 
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4.3.2 α-hydroxy acid Substitution at T150  
In α6, TrpB is at position 149, and Thr150 was substituted with threonine α-
hydroxy (Tah) to produce the desired amide-to-ester bond mutation.  As with the cation-π 
experiments, the EC50 of the agonist is determined at the wild-type and Tah mutant, and a 
loss of function indicates a functional hydrogen bonding interaction is present.  Typically, 
for these types of experiments, at least a 2-fold shift in EC50 is required to be considered 
meaningful.  Once the T150TAG mutation was made, the corresponding α6β2‡ mRNA was 
injected into oocytes alongside Thr- or Tah-bound tRNA, followed by dose response 
experiments with nicotine, acetylcholine, and TC299423. 
Nicotine experiences a 24-fold loss in function at the T150Tah mutant, suggesting 
it makes a potent hydrogen bond with the backbone carbonyl of TrpB.  To put such a loss 
of function into context, a similar shift in EC50 for ACh was observed when the cation-π 
interaction was ablated at TrpB, as described in Chapter 3.  ACh, on the other hand, did 
not experience any loss in function when applied to the Tah mutant.  This result was 
expected as ACh is a quaternary amine and has no hydrogen atom for which to donate into 
a hydrogen bond.  Finally, only a 4-fold loss of function was observed for TC299423.  This 
modest shift in EC50 indicates the agonist makes a hydrogen bond here, as it passes the 
Table 1. Investigating Hydrogen Bonding at α6β2 TrpB Carbonyl  
ACh EC50 (µM) nH Imax (µA) Fold N 
Thr 0.156 ± 0.004 1.31 ± 0.04 0.32 - 3.76   10 
Tah 0.199 ± 0.007 0.91 ± 0.03 0.48 - 3.27 1.3 10 
                        
Nicotine EC50 (µM) nH Imax (µA) Fold N 
Thr 0.11 ± 0.003 1.36 ± 0.04 0.19 - 2.69   16 
Tah 2.7 ± 0.1 1.24 ± 0.06 0.09 - 2.71 24 10 
                        
TC299423 EC50 (µM) nH Imax (µA) Fold N 
Thr 0.078 ± 0.002 1.07 ± 0.03 0.21 - 3.57   11 
Tah 0.30 ± 0.01 0.94 ± 0.03 0.12 - 4.13 3.8 13 
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two-fold threshold, but not as strong as nicotine. Perhaps, then, a different non-covalent 
interaction is primarily responsible for the binding of TC299423 to α6β2.  
4.4 Quantifying the α6β2-nicotine Hydrogen Bond 
4.4.1 The Double-Mutant Cycle Analysis 
 A classic technique in determining a functional coupling interaction between amino 
acids in a protein is the double-mutant cycle analysis.9–11  In this type of experiment, the 
two amino acids of interest are each mutated in a way that would attenuate the same non-
covalent interaction, both independently (as single-mutants) and simultaneously (as a 
double-mutant).  Changes in function for both the single-mutants and the double-mutant 
are then compared to wild-type.  If the fold-shift in EC50 of the double-mutant is merely a 
sum of each single-mutant fold-shift – that is, if the effects are additive – the single-mutant 
perturbations act independently of each other, and the two amino acids do not participate 
in a functionally coupled interaction.  If, on the other hand, the effect of the double-mutant 
proves to be non-additive, the amino acids are indeed functionally coupled.  The degree to 
which the double-mutant is additive or non-additive is expressed by an Ω value, which is 
defined as the product of the wild-type and double-mutant EC50 values divided by the 
product of the single-mutant EC50 values (Figure 2).  An Ω value other 1 indicates 
functional coupling between amino acids. Because Ω is a ratio of EC50 values, and EC50 is 
directly related to the binding energy, Ω values can be inserted into the free energy 
relationship to calculate a ΔΔG for the coupling energy between amino acids. 
To assess the nicotine hydrogen bond with the TrpB backbone carbonyl, a riff on 
the double-mutant cycle analysis was designed.  The first mutant in the analysis is the 
T150Tah substitution that results in an amide-to-ester backbone mutation.  The second 
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“mutant” uses a nicotine analog, wherein the pyrrolidine nitrogen is methylated to yield 
N’-methylnicotinium (N’MeNic in data tables).  As a quaternary amine, this compound is 
similar to ACh in that it is unable to donate a hydrogen bond.  By finding EC50 values for 
each condition – nicotine at wild-type, nicotine at T150Tah, N’-methylnicotinium at wild-
type, and N’-methylnicotinium at T150Tah – and determining whether or not the double-
Figure 2. Schematic of the double-mutant cycle analysis used to confirm and quantify a functional 
hydrogen bond between nicotine and the α6-β2 interface. An Ω value other than 1 indicates functional 
coupling between the mutants and provides conclusive evidence of a functional hydrogen bond.  Below 
are the equations used to calculate Ω and ΔΔG values. 
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mutant shows an additive loss of function, this mutant cycle will not only strengthen 
evidence that nicotine makes a hydrogen bond with the backbone carbonyl of Trp149 but 
will also quantify the strength of the hydrogen bond.  
4.4.2 Proof of Concept in α4β2 
 As a proof of concept, the double-mutant cycle analysis described above was first 
performed in the α4β2, because this subtype is more extensively studied and has a better 
understood binding map for nicotine than α6β2.  At α4β2, nicotine shows a 27-fold shift in 
EC50 at the T150Tah mutant, a major loss of function. When N’methylnicotinium is tested 
at the wild-type receptor, in this case the second “mutant” in the analysis, a 6-fold loss of 
function is observed.  If these two mutations were independent of each other and loss of 
function was due to an effect other than attenuating the hydrogen bond, an additive loss of 
function would be expected at the double-mutant close to 160-fold.  Instead, an EC50 of 
0.40 μM is observed, a 4-fold loss of function compared to wild-type that is not 
meaningfully different from the EC50 of N’methylnicotinium at wild-type (0.62 μM).  This 
lack of additivity is quantified with an Ω value of 42, which when entered into the free 
energy relationship reveals a ΔΔG value of -2.2 kcal/mol.  This value agrees with 
empirically determined hydrogen bond strengths of N-methylacetamide aggregates in 
carbon tetrachloride (ΔHo = -4.2 kcal/mol) and benzene (ΔHo = -3.6 kcal/mol).12,13 
Table 2. Bond Double Mutant Cycle Analysis of the Nicotine-TrpB Carbonyl Hydrogen in α4β2  
α4L9’Aβ2 Agonist T150 EC50 (µM) nH Imax (µA) Fold N 
WT Nicotine Thr 0.10 ± 0.01 1.4 ± 0.2 0.05 - 1.23 1 15 
Mut1 Nicotine Tah 2.7 ± 0.1 1.34 ± 0.04 0.11 - 1.23 27 6 
Mut2 N'MeNic Thr 0.62 ± 0.03 1.22 ± 0.07 0.02 - 0.60 6.2 10 
Mut1,2 N'MeNic Tah 0.40 ± 0.04 1.1 ± 0.1 0.08 - 0.42 4 12 
                        Ω 42 
ΔΔG (kcal/mol) -2.2 
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4.4.3 Quantifying the Nicotine Hydrogen Bond in α6β2‡ 
The same approach was taken in α6β2‡, for which nicotine has already been shown 
to experience a 24-fold loss of function at T150Tah.  The other single-mutant in this 
analysis, which is N’-methylnicotinium at wild-type α6β2‡, shows an even larger loss of 
function, with a 38-fold shift in EC50.  If these losses in function were not due to hydrogen 
bonding and instead were independent of each other, the double-mutant fold-shift would 
be totally additive with a nearly 900-fold increase in EC50 with respect to wild-type.  The 
double-mutant, N’-methylnicotinium at T150Tah, has instead an EC50 of 1.2 μM, a 10-fold 
shift away from wild-type.  This fold shift is not meaningfully different from the EC50 of 
nicotine at T150Tah (2.7 μM), and is only modestly different than N’-methylnicotinium at 
wild-type (4.2 μM), showing the effect is non-additive.  Overall, the mutant cycle has an 
Ω value of 88 and a ΔΔG of -2.6 kcal/mol, suggesting nicotine makes an even stronger 
bond with α6β2 than α4β2.  
4.5 Conclusion 
The work described in this chapter shows that nicotine makes a strong, quantifiable 
hydrogen bond with the backbone carbonyl of TrpB, though the effects with TC299423 are 
more modest.  These results offer an explanation for the lack of cation-π interaction 
observed between nicotine and the indole side chain of TrpB.  Such a strong hydrogen bond 
Table 3. Bond Double Mutant Cycle Analysis of the Nicotine-TrpB Carbonyl Hydrogen in α4β2   
α6β2
‡
  Agonist T150 EC50 (µM) nH Imax (µA) Fold N 
WT Nic Thr 0.11 ± 0 1.36 ± 0.04 0.19 - 2.69 1 16 
Mut1 Nic Tah 2.7 ± 0.1 1.24 ± 0.06 0.09 - 2.71 24 10 
Mut2 N'MeNic Thr 4.22 ± 0.19 1.03 ± 0.03 0.1 - 2.07 38 11 
Mut1,2 N'MeNic Tah 1.17 ± 0.08 0.93 ± 0.04 0.08 - 1.12 11 10 
                        Ω 88 
ΔΔG (kcal/mol) -2.6 
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might compensate for any losses of function that might have occurred by making cation-
π-attenuating mutations.  However, because the loss of function for TC299423 was so 
modest, and because a double mutant cycle is untenable with TC299423, the binding map 
for this agonist remains murky, with no perturbation made to the binding site causing more 
than a 6.7-fold loss in function.  What is clear is that as the picture of how agonists bind at 
the α6-β2 interface develops, the α6β2 subtype continues to present a unique and 
interesting pharmacology. 
4.6 Materials and Methods 
Molecular Biology 
Rat α6L9’S, α4L9’A (denoted as α4 throughout the section), β2L9’SLFM/AAQA and β2 
nAChRs were in the pGEMhe vector, a cDNA plasmid optimized for protein expression in 
Xenopus oocytes.  Site-directed mutagenesis was performed by PCR using the Stratagene 
QuikChange protocol and primers ordered from Integrated DNA Technologies (Coralville, 
IA).  Circular cDNA was linearized with SbfI (New England Biolabs, Ibswich, MA) and 
then transcribed in vitro using T7 mMessage mMachine kit (Life Technologies, Santa 
Clara, CA), with a purification step after each process (Qiagen, Valencia, CA).  Final 
concentrations were quantified by UV spectroscopy. 
Ion Channel Expression and α-hydroxy Acid Incorporation 
The cyanomethylester form of threonine α-hydroxy was synthesized, coupled to the 
dinucleotide dCA, and enzymatically ligated to UAG-suppressor 74-mer THG73 tRNACUA 
as previously described.2  The product was verified by MALDI time-of-flight mass 
spectrometry on a 3-hydroxypicolinic acid matrix.  Xenopus laevis oocytes (stage V to VI) 
were sourced from both a Caltech facility and Ecocyte Bio Science (Austin, TX).  The Tah-
tRNA was injected alongside α6β2‡ α6-T150UAG mRNA into oocytes at a 1:1 volume 
ratio, with an α6:β2 mRNA mass ratio of 10:1, resulting in 25 ng each of mRNA and tRNA 
injected per cell.  Cells were incubated 24-48 hours at 18oC in ND96 solution (96 mM 
NaCl, 2mM KCl, 1 mM MgCl2, and 5mM HEPES, pH 7.5) enriched with theophylline, 
sodium pyruvate, and gentamycine.  The fidelity of incorporation of Tah was confirmed 
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by charging tRNA with Thr in a wild-type recovery experiment.  Data from these 
experiments (reported as Thr in the data tables above) matched wild-type data, reported in 
previous chapters.  A read-through/reaminoacylation test serves as a negative control 
wherein a 76-mer tRNA is injected alongside mRNA.  Lack of current proved no detectable 
reaminoacylation at the Thr150 site. 
N’-methylnicotinium Synthesis 
Synthesis of N’-methylnicotinium was based on previously reported methods.14  All 
reagents were purchased from Sigma Alrdich (St. Louis, MO).  In a roundbottom flask, 
19.8 mL of nicotine was added to 250 mL of acetonitrile and excess sodium carbonate.  
Methyl iodide was added dropwise while stirring until 5.76 mL were added.  The reaction 
was stirred at room temperature for three days.  The reaction solution was filtered by 
vacuum and solids were discarded.  Solvent from the filtrate was removed by rotary 
evaporation until tan oil remained. Deionized water, 50 mL, was added to the oil and 
dissolved forming an orange solution.  Continuous chloroform extraction was performed 
on the orange solution for five days.  The aqueous layer was isolated and solvent was 
removed by rotary evaporation upon which crystals formed.  Product was recrystallized 
three consecutive times with hot isopropanol for an over 40% yield.  Further purification 
was achieved by iterative preparative HPLC (Waters, Milford, MA) using a 100% water 
solvent profile. 
1H NMR (500 MHz, Acetonitrile-d3) δ 8.80 (dd, J = 2.5, 0.8 Hz, 1H), 8.71 (dd, J = 4.8, 1.6 
Hz, 1H), 8.12 – 8.00 (m, 1H), 7.50 (ddd, J = 8.0, 4.8, 0.9 Hz, 1H), 5.06 (dd, J = 11.5, 8.0 
Hz, 1H), 3.95 – 3.69 (m, 2H), 3.12 (s, 3H), 2.75 (s, 3H), 2.74 – 2.63 (m, 1H), 2.57 – 2.42 
(m, 1H), 2.39 – 2.19 (m, 2H). 
Whole-Cell Electrophysiological Characterization 
Acetylcholine chloride and (-)-nicotine tartrate were purchased from Sigma Aldrich (St 
Louis, MO), while TC299423 (Targacept) was a generous gift.  N’-methylnicotinium 
iodide was prepared according to the procedure above.  Agonist-induced currents were 
recorded in TEVC mode using the OpusXpress 6000A (Molecular Devices, Sunnyvale, 
CA) at a holding potential of -60 mV in a running buffer of Ca2+-free ND96.  Agonists 
were prepared in Ca2+-free ND96 and delivered to cells via a 1 mL application over 15 sec 
followed by a 2 min wash.  Data from dose-response experiments were normalized, 
averaged, and fit to the Hill equation using Kaleidagraph (Synergy Software, Reading PA), 
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though data are visualized here with Prism (GraphPad Software, La Jolla, CA).  Error bars 
are presented as standard error of the mean, while EC50 and Hill coefficient errors are 
reported by Kaleidagraph and represent the sum of the squared error between the data and 
the calculated fit. 
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Chapter 5: Investigating a Dual Cation-π Interaction Trend 
with Secondary Amines at α4β2§ 
5.1 Abstract 
 Results presented thus far have shown that in α6β2, while ACh makes a functional 
cation-π interaction with TrpB, and nicotine makes a strong compensatory hydrogen bond 
with the backbone carbonyl of TrpB, the binding mode of TC299423 remains a mystery.  
In an effort to further understand TC299423 binding in other subtypes, the binding 
interactions of TC299423 with α4β2 were probed, and an interesting dual cation-π 
interaction with both TrpB and TyrC2 was observed.  This effect was reminiscent of results 
observed with metanicotine several years prior and revealed a possible trend amongst 
secondary amine agonists.  Varenicline, also a secondary amine, was probed at TrpB and 
TyrC2 to support that hypothesis and was shown to indeed form cation-π interactions at 
both residues. 
Finally, a structure-function study of sorts was designed with the secondary amine 
nornicotine, which only deviates in structure from nicotine by one methyl group on the 
pyrrolidine ring causing a shift from a tertiary amine to a secondary amine.  Nornicotine 
was found to form a cation-π interaction at TrpB, and preliminary results suggest it forms 
a functional cation-π interaction at TyrC2 as well. This result, if confirmed with more data, 
suggests that a dual cation-π interaction with TrpB and TyrC2 is a general feature of 
secondary amines, and offers new insight into the pharmacology of α4β2 nAChRs. 
                                                 
§ Much of the work described in this chapter was completed by Gabrielle S Tender (Caltech ’18) including 
structure-function studies of TC299423 (TrpB and TyrC2), Varenicline (TyrC2), and Nornicotine (TyrC2). 
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5.2 Introduction 
 The previous three chapters have investigated the binding patterns of ACh, nicotine, 
and TC299423 at α6β2 with results revealing that this nAChR subtype has a unique 
pharmacology.  Of particular interest, though, is TC299423, an agonist that was originally 
developed as a possible α6β2-selective agonist with properties showing promise for 
therapeutic use.1  However, whereas acetylcholine makes the canonical cation-π interaction 
with TrpB, nicotine and TC299423 do not.2  For nicotine, this is partially explained by a 
strong hydrogen bond was made with the backbone carbonyl of TrpB that might 
compensate for the attenuating effects of a fluorination series.  For TC299423, only a 
modest hydrogen bond was found at this site, and therefore further work is needed to 
explain its binding and activation of α6β2. 
 In order to understand more about TC299423, its binding interactions were studied 
in α4β2, which has been thoroughly characterized in previous work.3  The α4β2 binding 
site lies at the α4-β2 interface, and like all nAChR binding sites, it is composed of an 
aromatic box motif.  Five aromatic residues are contributed by four loops – TyrA (α4: 93), 
Trp B (α4: 149), TyrC1 (α4: 190), TyrC2 (α4:197), and TrpD (β2: 57).4  All agonists that 
have previously been studied at α4β2 demonstrate a cation-π interaction with TrpB, 
highlighting the anomalous nature the α6β2 results.5,6 
A recent computational study looking at the predicted cation-π binding ability of 
each aromatic residue in the AChBP aromatic box shows that each of these side chains can 
theoretically contribute cation-π binding energy to the overall binding energy of the ACh-
AChBP complex (modeled as tetramethylammonium): TyrA contributes 2.3 kcal/mol, 
TrpB contributes 8.3 kcal/mol, TyrC1 contributes 7.5 kcal/mol, TyrC2 contributes 8.0 
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kcal/mol, and TrpD contributes 4.8 kcal/mol.7  Though these predicted energy values 
suggest each member of the aromatic box plays some role in binding, previously reported 
structure-function studies show that they do not.  In studies investigating the behavior of 
nicotine at α4β2, the phenol group of TyrA was shown to form an important hydrogen 
bond, likely with another amino acid; a result determined from an O-methyltyrosine 
substitution causing a large loss of function.  However, TyrA shows no meaningful changes 
in EC50 when replaced with electron-withdrawing analogues and therefore does not make 
Figure 1. The structures and electrostatic potential maps of acetylcholine and nicotine are shown here for 
comparison to the secondary amine agonists used in this chapter: TC299423, metanicotine, nornicotine, 
and varenicline.  Maps are calculated with Hartree Fock 6-31G** and are shown on a scale of -10 to +150 
kcal/mol. 
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a cation-π interaction with nicotine.  TyrC2 shows no important phenol hydrogen bonding 
effects, as well as no cation-π interaction with nicotine.  This was established with a CN-
Phe substitution, which has similar electron-withdrawing effects as F2Phe but only causes 
a modest 2.7 fold-shift in EC50 (whereas metanicotine with CNPhe demonstrates a 6.1-fold 
shift in EC50).
8 
As TC299423 and nicotine showed in α6β2, binding patterns may differ from 
agonist to agonist and subtype to subtype.  This makes sense since it is well known that 
each subtype has a different pharmacology, function, and localization in the brain.9,10  Thus, 
it would be interesting and important to know if the variations in binding observed with 
TC299423 in α6β2 are consistent in α4β2.  This chapter will discuss work done making it 
evident that TC299423 makes a cation-π interaction with both TrpB and TyrC2, and it will 
explore whether this dual cation-π pattern is a general one for secondary amines.  Of the 
secondary amine agonists interrogated, all made a cation-π interaction with both TrpB and 
TyrC2.  This includes nornicotine – a nicotine analogue with the pyrolidine methyl group 
eliminated – proving that the additional cation-π interaction is indeed a feature of secondary 
amines at α4β2. 
5.3 Binding Studies of TC299423 at α4β2 
 TC299423 was found to not make a cation-π interaction with any aromatic residues 
probed in α6β2 as shown in Chapter 3.  Furthermore, it was only shown to make a modest 
hydrogen bond with the backbone carbonyl of TrpB in α6β2 as shown in Chapter 4.  These 
results showed TC299423 to behave quite differently than ACh and nicotine.  An important 
question to answer then, is if TC299423 also behaves uniquely at other subtypes, including 
α4β2.  This is an especially interesting question considering TC299423 was designed to be 
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an α6β2-selective ligand.  In order to learn the answer, TC299423 was probed for a cation-
π interaction with all of the aromatic residues using methods discussed in previous 
chapters. 
 At TrpB, TC299423 yet again shows some interesting results (Figure 2, Table 3).  
While there is a marked increase in EC50 with each additional fluorine substituent on the 
Figure 2.  For this and all fluorination plots presented in this chapter, the log of the fold-shift in EC
50
 is 
plotted against the M06 6-31G** calculated binding energy between a sodium ion and each non-canonical 
side chain for TC299423 at TrpB in α4β2.  While the maximum fold-shift at F
4
Trp is rather small for 
these types of experiments, the linear trend indicates the presence of a functional cation-π interaction 
between the indole side chain and the cationic agonist. 
Table 1. Investigating a Cation-π Interaction between TC299423 and TrpB in α4β2  
TrpB EC50 (μM) nH Imax (μA) Fold Shift N 
Trp 0.0234 ± 0.0009 1.39 ± 0.06 0.22 - 1.46 1 15 
F
1
Trp 0.0431 ± 0.0008 1.26 ± 0.03 0.12 - 1.2 1.8 11 
F
2
Trp 0.052 ± 0.001 1.21 ± 0.04 0.05 - 0.62 2.2 14 
F
3
Trp 0.129 ± 0.003 1.24 ± 0.03 0.11 - 1.41 5.5 12 
F
4
Trp 0.154 ± 0.007 1.12 ± 0.05 0.15 - 0.77 6.6 14 
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ring, the maximum fold-shift in EC50 observed was at F4Trp and was only a 6.6-fold 
increase.  While this is a modest loss of function – ACh experiences a 66-fold loss of 
function at F4Trp in the same subtype
5 – there is nevertheless a linear trend when the 
log(fold-shift) of each mutation is plotted against M06-calculated theoretical binding 
energies between a sodium ion and each side chain.  Thus, it can be said that TC299423 
makes a functional, if only modest, cation-π interaction with TrpB in α4β2. 
 TyrA was then probed for a cation-π interaction with TC299423, and yielded the 
same results previously published for nicotine.  That is, no functional cation-π interaction 
Figure 3. A fluorination plot for TC299423 at TyrC2 in α4β2.  The linear trend indicates the presence of 
a strong cation-π interaction between the indole side chain and the cationic agonist. 
Table 2. Investigating a Cation-π Interaction between TC299423 and TyrC2 in α4β2   
TyrC2 EC50 (μM) nH Imax (μA) Fold Shift N 
Phe 0.098 ± 0.003 1.09 ± 0.03 0.06 - 1.08 1 17 
F
1
Phe 0.144 ± 0.005 1.19 ± 0.04 0.05 - 0.38 1.5 12 
F
2
Phe 1.61 ± 0.07 1.28 ± 0.06 0.05 - 0.57 16 9 
F
3
Phe 2.95 ± 0.25 1.28 ± 0.11 0.07 - 0.18 30 7 
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was found.  TyrC2, though, showed an unexpected trend (Figure 3, Table 4).  While F1Phe 
only showed a modest 1.5-fold increase in EC50, the other points in the fluorination series 
showed large fold-shifts.  F2Phe resulted in a 16-fold increase, and F3Phe caused a 30-fold 
increase in EC50.  When translated into a fluorination plot, these results show a distinctly 
linear trend, showing that in addition to a cation-π interaction with TrpB, TC299423 makes 
an even stronger functional cation-π interaction at TyrC2. 
5.3 Binding Studies of Metanicotine at α4β2 
 The second cation-π interaction observed with TC299423 while surprising, was 
actually reminiscent of work done with metanicotine.  Metanicotine (also known as 
rivanicline, TC-2403, and RJR-2403) is an isomer of nicotine in which the pyrrolidine ring 
has been opened.11  This compound has antinociceptive effects in mice and is more potent 
and efficacious than ACh at α4β2 receptors.12,13  It had been proposed as a relatively 
selective activator of human α4β2 receptors, and therefore was of some interest to fully 
characterize at the α4-β2 binding site.  This study was completed early on relative to other 
projects presented in the thesis, and the results seemed anomalous until the data from 
TC299423 at α4β2 were collected several years later. 
 When metanicotine was used in a fluorination series at TrpB in α4β2 (Figure 4, 
Table 5), a strong cation-π interaction was observed, with F4Trp resulting in a 25-fold shift 
in EC50.  Though F1Trp is close to wild-type, the remaining points in the series show 
additive losses in function to form a linear trend when the log(fold-shift) is plotted against 
M06-calculated binding energies.  TyrC2 also shows a linear fluorination plot, with the 
F3Phe mutation causing 51-fold shift relative to Phe.  TyrA showed no meaningful changes 
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in metanicotine EC50 for fluorinated Phe residues relative to Phe.  Thus, metanicotine also 
forms dual functional cation-π interactions at both TrpB and TyrC2 in α4β2. 
 At the time these studies were completed, this dual cation-π feature, while 
remarkable, had no clear rationale.  However, once the same effect was observed with 
TC299423, both structures were compared to look for similarities that create a trend.  Both 
agonists are typical nicotinic pharmacophores in that they have a cationic amine moiety, a 
hydrogen bond donor associated with that amine, and a hydrogen bond acceptor several 
Figure 4. A fluorination plot for metanicotine at TrpB in α4β2.  The linear trend indicates the presence 
of a strong cation-π interaction between the indole side chain and the cationic agonist. 
Table 3. Investigating a Cation-π Interaction between metanicotine and TrpB in α4β2  
TrpB EC50 (μM) nH Imax (μA) Fold Shift N 
Trp 0.64 ± 0.02 1.32 ± 0.04 0.08 - 0.89 1 13 
F
1
Trp 0.79 ± 0.02 1.38 ± 0.03 0.12 - 0.80 1.2 16 
F
2
Trp 3.6 ± 0.1 1.54 ± 0.06 0.15 - 0.56 5.6 14 
F
3
Trp 13 ± 1 1.6 ± 0.1 0.07 - 0.30 20 12 
F
4
Trp 16 ± 2 1.3 ± 0.1 0.03 - 0.11 25 12 
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angstroms away.14  While metanicotine and TC299423 have critical differences in the 
moieties that make up these features – a pyridine versus a pyrimidine ring for the hydrogen 
bond acceptor, and a linear amine versus a hexahydroazocine – they are both secondary 
amines.  The question was then raised whether other secondary amines also had this 
interesting dual cation-π interaction.  If so, this would present an interesting and novel 
feature of secondary amine agonists and build on the current understanding of α4β2 
pharmacology. 
Figure 5. A fluorination plot for metanicotine at TyrC2 in α4β2.  The linear trend indicates the presence 
of a strong cation-π interaction between the indole side chain and the cationic agonist. 
Table 4. Investigating a Cation-π Interaction between metanicotine and TrpB in α4β2   
TyrC2 EC50 (μM) nH Imax (μA) Fold Shift N 
Phe 0.41 ± 0.03 1.16 ± 0.07 0.06 - 2.78 1 17 
F
1
Phe 0.86 ± 0.06 1.15 ± 0.08 0.04 - 0.07 2.1 11 
F
2
Phe 11 ± 1 0.6 ± 0.1 0.03 - 0.13 27 8 
F
3
Phe 21 ± 1 1.4 ± 0.2 0.04 - 0.24 51 12 
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5.4 Establishing a Binding Trend for Secondary Amines 
 The agonists discussed above, TC299423 and metanicotine, are both secondary 
amines and both make functional cation-π interactions with TrpB and TyrC2.  In order to 
determine whether these features are correlated – that is, whether a dual cation-π interaction 
is a defining feature of the secondary amine – more agonists must be tested.  Varenicline, 
sold and marketed by Pfizer as Chantix®, is an FDA-approved smoking cessation drug that 
Figure 6. A fluorination plot for Varenicline at TrpB in α4β2 as previously reported in Tavaresr da Silva 
et al.  The linear trend indicates the presence of a strong cation-π interaction between the indole side chain 
and the cationic agonist. 
Table 5. Previously Reported Cation-π Interaction between Verenicline and TrpB*  
TrpB EC50 (μM) nH Fold Shift   N 
Trp 0.0024 ± 0.0001 1.2 ± 0.1 1   15 
F
1
Trp 0.0057 ± 0.0002 1.2 ± 0.1 2.4   11 
F
2
Trp 0.0057 ± 0.0021 1.2 ± 0.1 2.4   14 
F
3
Trp 0.027 ± 0.001 1.3 ± 0.1 11   12 
F
4
Trp 0.056 ± 0.005 1.1 ± 0.1 23   14 
*Data as reported in Tavares da Silva et al 
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is thought to work by serving as a partial agonist to α4β2.15,16  Varenicline has a pyrazine 
hydrogen bond acceptor fused to a bridged tetrahydrobenzazepine group that serves as the 
cationic secondary amine group in the pharmacophore model.  This drug has previously 
been shown to form a cation-π interaction at TrpB (Figure 6, Table 5)6 in α4β2, with a 23-
fold shift in EC50 at F4Trp, but had never been analyzed at TyrC2. 
Nonsense-suppression based fluorination studies were conducted for varenicline at 
TyrC2.  Once again, F1Phe showed only a modest 1.4-fold shift in EC50 relative to Phe, but 
F2Phe and F3Phe showed 8.1-fold and 19-fold shifts in EC50, respectively (Figure 7, Table 
Figure 7. A fluorination plot for varenicline at TyrC2 in α4β2.  The linear trend indicates the presence of 
a strong cation-π interaction between the indole side chain and the cationic agonist. 
Table 6. Investigating a Cation-π Interaction between Varenicline and TyrC2 in α4β2    
TyrC2      EC50 (μM) nH Imax (μA) Fold Shift N 
Phe 0.0014 ± 0.0002 1.3 ± 0.14 0.04 - 0.14 1 10 
F
1
Phe 0.00201 ± 0.00009 1.45 ± 0.09 0.02 - 0.08 1.4 8 
F
2
Phe 0.0114 ± 0.00097 1.21 ± 0.11 0.02 - 0.1 8.1 12 
F
3
Phe 0.0267 ± 0.0016 1.08 ± 0.06 0.02 - 0.09 19 8 
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6).  The corresponding fluorination plot shows a linear trend confirming that varenicline 
makes a strong cation-π interaction with TyrC2 in α4β2. 
With the results from varenicline, three agonists have now been demonstrated to 
form functional cation-π interactions with both TrpB and TyrC2 in α4β2.  These three drugs 
have distinctly varied structural features at both their hydrogen bond acceptor and cationic 
ends (Figure 1).  However, they all share in common a secondary amine moiety.  While 
having three secondary amine agonists display dual cation-π interactions is highly 
indicative of a trend, it does not definitively prove a correlation.  To do this, a structure-
function study of sorts was designed.  Transforming nicotine – which has been shown to 
only form a cation-π interaction at TrpB in α4β2 – into a secondary amine should establish 
that it is solely the difference in the order of the amine that is responsible for the dual 
cation-π interaction effect.  The demethylated, secondary amine version of nicotine is 
nornicotine, a natural component of tobacco that is a precursor to the well-documented 
carcinogen N’-nitrosonicotine that is a byproduct of the curing process.17  This compound 
is available commercially and was probed for binding interactions at TrpB and TyrC2. 
Nornicotine has an EC50 of 1.8 μM, a 20-fold shift compared to nicotine, showing 
that it is a significantly less potent agonist.  The fluorination plot of nornicotine at TrpB 
shows a cation-π interaction, with F4Trp resulting in a 27-fold shift in EC50 (Figure 8, Table 
7).  Compared to nicotine, which shows a 47-fold loss in function at F4Trp, this is perhaps 
a less strong but still functionally important cation-π interaction.  Preliminary data for 
TyrC2 shows the same type of trend seen for other secondary amine agonists analyzed in 
this chapter (Figure 9, Table 8).  The YC2Phe mutant has an EC50 of 3.7 μM, only a slight 
loss of function from wild-type.  The F1Phe and F2Phe mutants have EC50 values of 5.6 
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and 26 μM respectively.  These mutations represent a 1.5-fold and 7-fold shift in EC50 from 
wild-type, results that are consistent with the other agonists (varenicline had 1.4-fold and 
8.1-fold shifts in EC50 at these mutants).  The fluorination plot for these three values shows 
a fairly linear trend (R2 = 0.89) that can be used to predict a fold-shift for F3Phe of 12.7, 
and an EC50 of 46 μM.  While this theoretical fold-shift is lower than other secondary amine 
agonists (summarized in Table 9), it is still indicative of a functional cation-π interaction.  
If future data collected at F3Phe substantiates the trend, it would provide definitive proof 
that a unique and general feature of secondary amine agonists is the formation of dual 
cation-π interactions with TrpB and TyrC2. 
Figure 8. A fluorination plot for nornicotine at TrpB in α4β2.  The linear trend indicates the presence of 
a strong cation-π interaction between the indole side chain and the cationic agonist. 
 Table 7. Investigating a Cation-π Interaction between Nornicotine and TrpB in α4β2   
TrpB EC50 (μM) nH Imax (μA) Fold Shift N 
Trp 1.65 ± 0.06 1.29 ± 0.05 1.33 - 9.37 1 13 
F
1
Trp 4.6 ± 0.2 1.26 ± 0.05 0.27 - 0.9 2.8 16 
F
2
Trp 10.5 ± 0.7 1.31 ± 0.08 0.04 - 0.11 6.4 8 
F
3
Trp 26 ± 2 1.5 ± 0.1 0.05 - 1.28 16 16 
F
4
Trp 44 ± 4 1.15 ± 0.08 0.95 - 1.51 27 8 
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5.5 Conclusions 
 Structure-function studies of four different agonists, with a variety of structural 
features but a common secondary amine moiety, have each demonstrated a functional 
cation-π interaction with both TrpB and TyrC2 in α4β2.  The computational studies of 
AChBP discussed earlier are predictive of this effect (TrpB contributed 8.3 kcal/mol and 
TyrC2 contributed 8.0 kcal/mol to the overall binding of tetramethylammonium), but it has 
Figure 9. A preliminary fluorination plot for nornicotine at TyrC2 in α4β2.  The linear trend indicates 
the presence of a strong cation-π interaction between the indole side chain and the cationic agonist though 
data at F
3
Phe would make this case stronger.  If the trend holds with more data, it would be especially 
strong evidence that secondary amines follow a dual cation-π interaction trend in α4β2 as the only 
difference between this agonist and nicotine is the shift from a tertiary amine to a secondary amine. 
 Table 8.  Investigating a Cation-π Interaction between Nornicotine and TyrC2 in α4β2   
TyrC2 EC50 (μM) nH Imax (μA) Fold Shift N 
Phe 3.7 ± 0.4 1.2 ± 0.1 0.07 - 1.42 1 20 
F
1
Phe 5.6 ± 0.6 1.2 ± 0.1 0.06 - 0.1 1.5 4 
F
2
Phe 26 ± 2 1.6 ± 0.1 0.05 - 0.08 7.0 5 
F
3
Phe No Data  
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not been observed with either ACh or 
nicotine.  While the nornicotine 
experiments could definitively show the 
dual cation-π interaction to be a feature of 
secondary amines, they do not offer 
substantial evidence explaining why. 
A likely hypothesis is that the 
secondary amine has less local steric bulk, and therefore Loop C is able to come closer to 
the agonist forming a strong and functionally important cation-π interaction.  Along the 
same lines, the agonist may be freer to move around the binding site with one less methyl 
group and orient in a way that brings the cation closer to both aromatic residues than a 
tertiary or quaternary amine would allow.  An alignment of two AChBP structures, one 
crystallized with the tertiary amine nicotine and the other with varenicline, could 
potentially add extra insight.  However, as seen in Figure 10, the positions of TrpB in each 
structure superimpose almost perfectly, and TyrC2 only shows a slight rotation of the 
phenol ring, though not enough to cause any changes in cation-π binding ability.  The 
positions of the cationic center of each agonist also overlap closely.  This could be a result 
of differences between AChBP and α4β2; recall that that their extracellular regions only 
share about 30% sequence identity.  It is also important to remember that crystal structures 
only offer a snapshot of one confirmation, and that the lack of the methyl group may allow 
a conformation shifts not visualized by the crystal structure.  Thus, the crystal structures 
neither substantiate the sterics-based hypothesis nor rule it out. 
Table 9: Summary of Relative Cation-π Interaction 
Strengths at TrpB and YC2 for Secondary Amines  
Agonist 
Fold Shift: 
F
4
Trp 
Fold Shift: 
F
3
Phe 
ACh 66 --- 
Nicotine 47 --- 
TC299423 6.6 30 
metanicotine 25 51 
varenicline 23 19 
nornicotine 27 12.7* 
*predicted using linear regression result from Figure 9  
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Future studies should investigate the cause of the dual cation-π interaction feature 
of secondary amine agonists described here.  They should also determine whether this 
effect is present in other subtypes such as muscle-type, α7, and α6β2 (though TC299423 
was not observed to form a cation-π interaction at TyrA or TyrC2).  If the dual cation-π 
interaction is unique to α4β2, which evidence in this chapter suggests, it may be an 
intriguing feature to consider when designing subtype-selective agonists. If it proves to be 
universal, or at least common amongst several subtypes, an important aspect of nAChR 
function will have been revealed.  Either way, this is a new and novel pharmacological 
phenomenon of a ligand gated ion channel that offers exciting new ways of thinking about 
ligand-binding. 
Figure 10. Structures of AChBP crystallized with varenicline (lighter shades) and nicotine (darker 
shades) from PDBs 1UW6 and 4AFT.  The primary face is in blue, the complementary face is in tan, and 
the aromatic box is highlighted in green.  Note that neither TrpB nor TyrC2 show any meaningful 
movement.  It is important to note, however, that AChBP only shares 30% identity with the extracellular 
region of α4β2 and does not rule out any possible explanations for differences in binding.  Structures 
were aligned with PyMol Molecular Graphics System. 
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5.6 Materials and Methods  
Molecular Biology 
Rat α4L9’A (described as wild-type and/or α4 throughout this chapter) and β2 nAChRs 
were in the pGEMhe vector, a cDNA plasmid optimized for protein expression in Xenopus 
oocytes.  Site-directed mutagenesis was performed by PCR using the Stratagene 
QuikChange protocol and primers ordered from Integrated DNA Technologies (Coralville, 
IA).  Circular cDNA was linearized with SbfI (New England Biolabs, Ibswich, MA) and 
then transcribed in vitro using T7 mMessage mMachine kit (Life Technologies, Santa 
Clara, CA), with a purification step after each process (Qiagen, Valencia, CA).  Final 
concentrations were quantified by UV spectroscopy. 
Ion Channel Expression 
Xenopus laevis oocytes (stage V to VI) were sourced from both a Caltech facility and 
Ecocyte Bio Science (Austin, TX).  Oocytes were injected with 50 nL solution containing 
either 5 or 10 ng mRNA, injected in a 1:2 ratio.  Cells were incubated 24-48 hours at 18oC 
in ND96 solution (96 mM NaCl, 2mM KCl, 1 mM MgCl2, and 5mM HEPES, pH 7.5) 
enriched with theophylline, sodium pyruvate, and gentamycine. 
Non-canonical Amino Acid Incorporation 
The cyanomethylester form of NVOC-protected tryptophan and phenylalanine analogues 
was coupled to dinucleotide dCA and enzymatically ligated to UAG-suppressor 74-mer 
THG73 tRNACUA as previously described.18  The product was verified by MALDI time-of-
flight mass spectrometry on a 3-hydroxypicolinic acid matrix.  The non-canonical amino 
acid-coupled tRNA was deprotected by photolysis either on a 500 W Hg/Xe arc lam, 
filtered with Schott WG-320 and UG-11 filters, or with an M365LP1 365 nm 1150 mW 
LED lamp (Thor Labs, Newton, NJ) immediately prior to coinjection with mRNA 
containing the UAG mutation at the site of interest.  mRNA and tRNA were typically 
injected in a 1:1 or 1:2 volume ratio in a total volume of 50 or 75 nL respectively so that 
25 ng of mRNA was injected per cell.  In cases where observed agonist-induced currents 
were low after 48 hour incubation – likely due to low receptor protein expression – a second 
injection of mRNA and tRNA was performed after 24 hours.  The fidelity of non-canonical 
amino acid incorporation was confirmed at Trp with a wild-type recovery experiment 
where tryptophan was loaded onto tRNA.  If this experiment yielded similar to EC50 to 
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wild-type then the cell incorporated the charged residue and nothing else.  This was 
accomplished with the Tyr sites by comparing tRNA charged with Phe to a conventional 
Y-Phe mutation.  A read-through/reaminoacylation test served a negative control by 
injecting unacylated full-length 76-mer tRNA.  Lack of current proved no detectable 
reaminoacylation at the TrpB site. 
Whole-Cell Electrophysiological Characterization   
(S)-nornicotine hydrochloride was purchased from Matrix Scientific (Columbia, SC) while 
varenicline (Pfizer), metanicotine and TC299423 (Targacept) were generous gifts.  
Agonist-induced currents were recorded in TEVC mode using the OpusXpress 6000A 
(Molecular Devices, Sunnyvale, CA) at a holding potential of -60 mV in a running buffer 
of Ca2+-free ND96.  Agonists were prepared in Ca2+-free ND96 and delivered to cells via 
a 1 mL application over 15 sec followed by a 2 min wash.  Data from dose-response 
experiments were normalized, averaged, and fit to the Hill equation using Kaleidagraph 
(Synergy Software, Reading PA), though data are visualized here with Prism (GraphPad 
Software, La Jolla, CA).  Error bars are presented as standard error of the mean, while EC50 
and Hill coefficient errors are reported by Kaleidagraph and represent the sum of the 
squared error between the data and the calculated fit. 
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Chapter 6: Evaluating a Predicted Interfacial Hydrogen Bond 
Interaction Across the α4-β2 Interface** 
6.1 Abstract 
 Several AChBP crystal structures report a predicted hydrogen bond between the 
indole NH of TrpB and lobeline, a compound with potential for use as a smoking cessation 
aid.  In α4β2, the napthylalanine (NpAla) substitution used to probe this hydrogen bond 
interaction yielded inconclusive results for lobeline, but showed an interesting gain-of-
function when tested with acetylcholine.  One possible explanation for that gain of function 
is that the indole NH is actually hydrogen bonding with a backbone carbonyl on Loop E 
and stabilizing the closed state.  Thus, when the interaction is eliminated, the state 
equilibrium shifts more toward the open state and causes a decrease in EC50.  This Loop 
B-Loop E hydrogen bond was tested using several different double-mutant cycle analysis 
strategies, made complicated because the carbonyl of interest is associated with a leucine 
that is followed by two conserved prolines.  The only approach taken that worked preserved 
the Pro-Pro motif and instead substituted Leu119 with trifluoroalanine (F3Ala), which due 
to inductive effects weakens the carbonyl’s ability to serve as a hydrogen bond acceptor.  
After this strategy was validated by both computational and empirical NMR studies, a 
double mutant cycle was executed using NpAla and F3Ala as the two mutants.  The double-
mutant proved to be additive, with an Ω value of 1.7 and a ΔΔG of -0.3 kcal/mol, thus 
                                                 
** Work presented in this chapter was borne out of a wonderful collaboration with Matthew R Davis, who 
performed all of the computational and NMR studies and contributed to project direction and experimental 
design. 
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disproving the hypothesis that the TrpB NH makes a hydrogen bond with a backbone 
carbonyl on Loop E; however, a useful hydrogen bond probe was developed in the process. 
6.2 Introduction  
 Since the first crystal structure of 
AChBP was published,1 the number of 
pLGIC receptors and corresponding 
homologues in the protein database has 
increased rapidly.2,3  These structures offer 
a wealth of information, and knowing the 
position and proximity of amino acids in 
relation to each other allows for predictions 
to be made about the types of interactions 
that might influence protein structure and 
function.  Two of these structures, both of lobeline bound to AChBP from two different 
organisms, published six years apart, predict a hydrogen bond between lobeline and the 
indole NH of a tryptophan that would align with TrpB (Figure 1).4,5  Lobeline is a natural 
component of Indian tobacco (Lobelia inflate) and consists of two phenyl rings linked to a 
methylated piperidine ring by a 2-keto-ethyl and a 2-hydroxyethyl group.  It has been 
shown to exhibit both agonist and antagonist properties at α4β2 depending on the 
concentration.6  Lobeline has previously been examined as a smoking cessation drug, as 
well as a possible lead compound for vesicular monoamine transporter ligands.7,8  
Therefore, there is some interest in determining whether these predicted interactions are 
functionally important in α4β2. 
Figure 1.  Shown above is the crystal structure 
(PDB: 4AFH) of ct-AChBP bound to lobeline (in 
gray) that predicts a hydrogen bond between the 
2-keto-ethyl group and the indole NH of TrpB 
(shown in pink). 
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 To probe for an interaction between the indole NH of a tryptophan and an agonist 
carbonyl, the simplest structure-function study eliminates the NH all together by 
substituting the tryptophan of interest with 1-napthylalanine (NpAla).  If the 2-keto-ethyl 
group of lobeline is indeed making a hydrogen bond with the TrpB in α4β2, then upon 
mutation to NpAla, there should be an increase in EC50.  Instead, the fold-shift in EC50 with 
lobeline at this mutation is just at the two-fold threshold.  Thus, there is likely not a 
meaningfully important hydrogen bond between lobeline and the indole ring.  As a negative 
Figure 2.  A Trp NH hydrogen bond can be probed using 1-napthylalanine (NpAla), which replaces the 
indole side chain with a naphthyl ring.  Shown below the structural schematic are results from dose 
response experiments at wild-type and the NpAla with both lobeline and ACh.  Note that the agonists 
experienc a shift in EC
50
 in opposite directions. 
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control, ACh was also tested at this mutant, which has been previously been explored at 
the muscle-type nAChR NpAla mutant and shown to have no shift in the EC50.
9  
Interestingly, a different effect was observed with ACh at α4β2 than either the muscle-type 
or lobeline experiments yielded, and a five-fold decrease in EC50 was observed.  Because 
ACh is a quaternary amine and cannot form a hydrogen bond, the gain of function shift is 
likely not due to ligand-binding.  Furthermore, gain of function mutations are not 
commonly encountered when employing non-canonical amino acid mutagenesis in the 
binding region of pGLIC receptors,10 and so this NpAla mystery warranted further 
investigation, as it could potentially reveal important details about α4β2 function. 
 Because EC50 is a composite measurement of both binding and gating, if the NpAla 
gain-of-function result is not due to changes in ligand-binding, it is then likely due to 
gating.  One way to conceptualize nAChR function is through an oversimplified three state 
model (Figure 3).11  The first state consists of a closed inactive ion channel and unbound 
ligand.  In the second state, the receptor is bound to ligand, but still in a closed and inactive 
state.  In the third state, the receptor is bound to ligand and open to conduct a flow of 
positively charged ions.  The receptor is in a dynamic equilibrium between the three states, 
with Kd serving as the equilibrium constant describing the binding event, and Θ serving as 
the equilibrium constant describing the gating event.  EC50 is equal to Kd divided by (1 + 
Θ); therefore if Kd is unchanged by a mutant, and a decrease in EC50 is observed, that must 
Table 1. Investigating hydrogen bonding at TrpB NH  
Lobeline EC50 (uM) nH Imax (uA) Fold Shift N 
WT 0.20 ± 0.03 1.2 ± 0.1 0.12 - 0.57 1 10 
NpAla 0.40 ± 0.05 1.18 ± 0.03 0.03 - 0.10 2.0 3 
  
ACh EC50 (uM) nH Imax (uA) Fold Shift N 
WT 0.5 ± 0.01 1.19 ± 0.03 4.25 - 30.31 1 10 
NpAla 0.11 ± 0.003 1.16 ± 0.03 0.05 - 19.77 0.2 18 
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be due to an increase in Θ.  Such an increase in Θ is then likely to be caused by either a 
destabilization of the closed ligand-bound state, or a stabilization of the open ligand-bound 
state.   
In the case of the Trp-to-NpAla mutation, a hydrogen bond donor is eliminated, 
resulting in a five-fold gain of function, and so it seems likely that the resulting decrease 
in EC50  is due to a destabilization of the closed state.  To put this in simpler terms, one 
possible hypothesis is that the indole NH makes a hydrogen bond with another amino acid, 
and when that binding interaction is eliminated with NpAla, the closed state is destabilized, 
and it becomes easier for the receptor to open upon ligand-binding.  A greater proportion 
Figure 3.  This schematic depicts the simple three state model used to describe ligand-gated ion channel 
function.  The receptor, in this case α4β2 nAChR, is in a dynamic equilibrium among all three. The 
binding event is characterized by K
d
, while the gating event is characterized by Θ.  EC
50
 is a composite 
measurement taking into account both binding (K
d
) and gating (Θ). 
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of receptors in the open state upon ligand binding means a higher Θ, which results in a 
lower EC50. 
In order to prove this hypothesis, the indole ring’s hydrogen bond partner must be 
identified and confirmed.  A crystal structure of AChBP bound to nicotine shows that the 
TrpB indole ring is in proximity to a carbonyl associated with a leucine on Loop E of the 
β2 subunit, L119 (Figure 4).12  If a closed-state-stabilizing hydrogen bond exists between 
TrpB and another amino acid, it is most likely Leu119.  As shown in Chapter 4, a good 
way to determine whether amino acids participate in a coupled interaction, such as a 
hydrogen bond, is via a double-mutant cycle analysis.  Attenuating or eliminating the 
hydrogen bond by mutating the TrpB indole NH and the Leu119 carbonyl, both 
independently and together, will provide the necessary information to determine if this 
interaction is important, and furthermore, if it is responsible for the gain of function 
discussed above.   
Figure 4.  This crystal structure (PDB: 1UX2) view predicts a hydrogen bond between Trp149 (on 
Loop B, in orange) and Leu119 (on Loop E, in green) 
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The typical structure-function strategy for attenuating a carbonyl’s ability to serve 
as a hydrogen bond acceptor has been described in Chapter 4 as well.  By substituting the 
i + 1 residue to the carbonyl of interest with an α-hydroxy acid, the backbone is mutated 
from an amide to an ester.  Because of the loss of resonance when the nitrogen is replaced 
with an oxygen, the carbonyl becomes a weaker hydrogen bond acceptor, and the binding 
energy of the interaction decreases.  This strategy can theoretically work in any situation 
as long as the i + 1 residue can be converted to an α-hydroxy acid.  In the Loop B-Loop E 
hydrogen bond under investigation, herein lies a massive issue:  Leu119 is part of a 
conserved Leu-Pro-Pro motif, and proline α-hydroxy is not an option. 
The primary goal of this chapter is then two-fold – develop a new means of probing 
for hydrogen bonding for the Leu-Pro-Pro motif, and use this technique to determine 
whether TrpB makes a closed state-stabilizing hydrogen bond to LeuE.  Ultimately, it 
seems the best approach is to use fluorinated side chains at the same position (i + 0) to 
withdraw electron density away from the carbonyl.  Using this method, it is evident that 
the hydrogen bonding interaction predicted by structure and hypothesized to explain the 
gain of function seen with NpAla is not actually functionally relevant, and that this 
mysterious effect requires other rationale. 
6.3 Strategies to Probe for Hydrogen Bonding at Loop E Leu-Pro-Pro 
 The hypothesis being tested is that the reason NpAla causes a gain-of-function 
response from the receptor is due to a functional hydrogen bond that stabilizes the closed 
state.  Therefore, NpAla is always an element in the cycle.  The chief issue to overcome is 
attenuating the hydrogen bonding ability of the LeuE carbonyl, since the i + 1 residue is a 
proline and cannot be simply mutated to an α-hydroxy acid.  Thus, each of the following 
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strategies follow a similar road map.  They all propose a double-mutant cycle analysis 
where the first mutant substitutes TrpB with NpAla, and the second mutant attenuates the 
ability of the LeuE carbonyl to form a strong hydrogen bond using methods beyond what 
have already been established.  If the hypothesis is correct, then attenuating that carbonyl 
should also result in a gain of function; however, the double mutant cycle analysis ensures 
those fold-shifts are due to this specific proposed hydrogen bond, and not extraneous 
effects. 
6.3.1 The δ-amino acid Strategy 
 The first approach taken to determine if Loop B and Loop E make an interfacial 
hydrogen bond was also conceptually and practically the most complicated.  Because the 
Leu-Pro-Pro motif is so well conserved (the vicinal di-proline is found in almost every 
nAChR subunit from almost every organism in which the gene has been cloned), a strategy 
was conceived that retained both side chains while eliminating the carbonyl all together.  
Figure 5.  The proposed hydrogen bond that is stabilizing the closed state is between the indole NH of 
Trp149 (Trp B) and Leu119 (of Loop E). Typically an α-hydroxy acid at the i + 1 position would be used 
to attenuate the hydrogen bond, but in this case that position is occupied by a highly conserved proline.  
The strategy depicted here proposes a δ-amino acid containing the Leu and Pro side chains but lacking a 
carbonyl group.  This idea was quickly demonstrated to be impossible when the ribosome was unable to 
insert β-alanine at even the most promiscuous sites. 
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However, replacing the carbonyl with a methylene group would also destroy the peptide 
bond and require the incorporation of a δ amino in place of Leu119 and Pro120 (Figure 5). 
It was unclear, and perhaps unlikely, that the oocyte ribosome (or any ribosome for 
that matter) would be able to incorporate an amino acid with an extended backbone, let 
alone a δ-amino acid with two relatively bulky side chains.  Therefore, initial nonsense 
suppression experiments tested β-alanine, a β-amino acid with no side chain structurally 
more similar to glycine than alanine.  The appropriate dCA-β-alanine was synthesized and 
ligated to THG73 and then tested at various glycine sites in the muscle-type nAChR.  These 
tests either resulted in no functional expression or in observed agonist-induced currents at 
both β-alanine and 76mer control conditions.  These results suggested that not even a β-
amino acid could make it through the translation machinery, and further attempts to 
incorporate the Leu-Pro δ-amino acid were subsequently abandoned in favor of simpler 
approaches. 
6.3.2 The Gly-Gah Strategy 
 After attempting such a shoot-the-moon strategy, in deference to Occam’s razor, 
the perhaps simplest approach was attempted next.  Here, any potential importance of the 
conserved vicinal di-proline motif was disregarded, and a double mutant cycle was 
designed where Pro120 is first mutated to a glycine.  The P120Gly mutant would then serve 
as the cycle’s “wild-type” and provide a baseline for calculating the single- and double-
mutant fold shifts in EC50.  In this analysis, the first single-mutant consists of the NpAla 
substitution at TrpB in the α4 subunit and the P120Gly mutation in the β2 subunit.  The 
other single-mutant is a glycine to glycine α-hydroxy (Gah) mutation in the β2 subunit.  
Since P120Gly is i + 1 to Leu119, a Gah substitution causes an amide-ester backbone 
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mutation, and makes the carbonyl of interest a weaker hydrogen bond acceptor.  If the 
predicted hydrogen bond is present, this mutation should be accompanied with a decrease 
in EC50. Finally, the EC50 of a NpAla-L119 double-mutant is evaluated for additivity.  If 
the Gly-Gah mutation alone causes a gain of function, and the cycle shows an Ω value 
other than one, the closed-state hypothesis would be proven correct. 
  The double-mutant in this case requires incorporation of two different non-
canonical amino acids in two different protein chains – NpAla in α4 and Gah in β2.  
Double- and triple-incorporations have previously been reported in the muscle-type 
nAChR.  In one example, two adjacent residues in the α1 subunit were substituted using 
nonsense suppression, with the codon of Phe135 mutated to TAG and Pro136 to TGA (a 
TAA stop codon was used to terminate translation).13  Two different suppressor tRNAs, 
THG73 (UAG) and TQOPS’ (UGA), were then used to incorporate a different non-
Figure 6.  On the left is the proposed double mutant cycle using a P120Gly mutant as the “wild-type” 
and Gah and NpAla as the single-mutants.  This strategy failed as the 76-mer control had the same exact 
EC
50
 as the conventional P120G mutant as shown by the overlapping dose response curves.  Above the 
plot are the structures of Gly and Gah. 
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canonical amino acid at each site.  In the other example, a different non-canonical amino 
acid was simultaneously incorporated into each of the α1, β1, and δ subunits using both 
nonsense suppression and frameshift suppression.14  Both strategies proved to be quite 
effective, though it was not certain that either would work in a neuronal subtype. 
 In the Gly-Gah double-mutant studies, α4 Trp149 was mutated to a TAG stop codon 
and suppressed with THG73 tRNA, and β2 Leu119 was mutated to a TGA stop codon and 
suppressed with TQOPS’ tRNA.  The TQOPS’ suppressor tRNA has an added benefit of 
being less likely to get reaminoacylated with endogenous amino acid.15  This characteristic 
is important, as sites on Loop E are often quite promiscuous in that they can tolerate a wide 
range of amino acid substitutions, and they are therefore more likely to have an issue with 
reaminoacylation. 
In the case of this current study, that issue proved to be fatal for the Gly-Gah 
strategy.  All four scenarios of the double mutant cycle analysis showed high currents and 
monophasic dose response curves.  The Trp-Gly and Trp-Gah EC50 values were not 
meaningfully different, the NpAla cases showed the same five-fold decrease in EC50, and 
no changes were observed between the Gly-NpAla and Gah-NpAla mutation.  These results 
would have proven that no hydrogen bond exists – the calculated Ω value only results in a 
ΔΔG of 0.2 kcal/mol.  However, the critical reaminoacylation positive control failed.  The 
 Table 2.  Investigating an Interfacial Hydrogen Bond with a Gly-Gah Mutant Cycle 
α4β2 W149 P120 EC50 (µM) nH Imax (µA) Fold Shift N 
WT Trp Gly 31.7 ± 0.8 1.49 ± 0.04 2.13 - 18.41 1 13 
Mut1 NpAla Gly 9 ± 0.3 1.34 ± 0.05 0.04 - 0.53 0.3 14 
Mut2 Trp Gah 23.3 ± 0.8 1.69 ± 0.09 0.68 - 9.59 0.7 6 
Mut1,2 NpAla Gah 9 ± 1 1.09 ± 0.13 0.17 - 0.33 0.3 2 
                        Ω 1.4 
ΔΔG (kcal/mol) -0.2 
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dose response curve that was generated from injecting both Trp-bound THG73 and 76-mer 
TQOPS’ (full length, but non-acylated) alongside the double stop codon mutant mRNA 
were identical to the Trp-Gly and Trp-Gah experiments.  Additionally, a no-nonsense 
experiment using wild-type α4 and conventionally mutated P120G β2 had a dose response 
curve that overlapped perfectly with the previous two conditions (Figure 6). 
The endogenous amino acid found to reacylate both THG73 and TQOPS’ is 
glutamine,16 which suggests that Pro120 can tolerate mutation to both glycine and 
glutamine, and that both substitutions have the same effect on EC50.  That in and of itself 
might be interesting, but for the purposes of identifying and confirming an interfacial 
hydrogen bond between TrpB and Leu119, the Gly-Gah double mutant strategy is not 
viable.   
6.3.3 The Fluorination Strategy 
Clearly, the vicinal di-proline of the conserved Leu-Pro-Pro motif is important for 
protein function and should not be manipulated.  Taking this into account, the next strategy 
attempts to attenuate the hydrogen bond accepting ability of the carbonyl from the other 
side; that is, by mutating the actual residue associated with the carbonyl.  The goal here is 
to attenuate the hydrogen bond interaction without affecting the protein backbone.  No 
matter the approach, the electronegativity of the carbonyl oxygen needs to be decreased.  
On first principles, adding electron-withdrawing groups in close proximity to the carbonyl 
group can potentially cause such an effect.  Adding electron-withdrawing substituents like 
Table 3. Conventional Mutagenesis Results at β2 L119  
α4β2 EC50 (µM) nH Imax (µA) N 
WT 0.50 ± 0.01 1.19 ± 0.03 4.24 - 30.31 10 
L119A 1.49 ± 0.08 1.21 ± 0.06 3.05 - 15.98 11 
L119V 1.73 ± 0.06 1.12 ± 0.03 5.93 - 26.20 11 
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fluorine at the α-carbon runs the risk of causing an elimination reaction forming an imino 
acid.  However, β- and γ- substituted trifluoro groups should still have an inductive 
attenuating effect while avoiding potential elimination reactions.   
Leucine has a β-carbon methylene group that could possibly be fluorinated, but 
using trifluoroalanine (F3Ala) and hexafluorovaline (F6Val) provided an approach with 
more electron withdrawing atoms and less challenging synthetic routes.  The fluorination 
strategy for probing a Loop B-Loop E interfacial hydrogen bond thus employs a double-
mutant cycle analysis that substitutes these fluorinated amino acids at Leu119 as one of the 
single-mutants.  Of course this requires using the L119Ala or L119Val mutants as the 
cycle’s “wild-type” reference.  Conventional mutagenesis shows the receptor experiences 
a roughly 3-fold gain in EC50 with both the Ala and Val mutations, a modest loss of function 
that should not create problems for the double-mutant cycle (Table 3).  As per other 
proposed cycles, the TrpB NpAla mutation serves as the second mutation.  A NpAla-F3Ala 
or NpAla-F6Val double-mutant would then serve as a way to measure additivity and 
confirm the presence of a functional hydrogen bond between these two residues. 
Initial experiments show that nonsense suppression is possible at both sites 
simultaneously. In these wild-type recovery tests, well-behaved large current traces are 
observed with monophasic dose response curves.  A 76-mer ne control experiment does 
not result in functional expression at the Trp149 site, but does show large agonist-induced 
currents at L119.  The latter, however, produces a dose response curve that never turns 
over as the ACh concentration approaches 1000 μM.  While these initial results are 
promising, this method of attenuating the hydrogen bond is new, and relies on first 
principles.  In order to be certain any results from the double-mutant cycle are meaningful, 
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the fluoro-analogues must be tested to ensure they are causing the desired effect. This will 
be done through computational as well as NMR-based studies.  If these analyses prove that 
F3Ala and F6Val are an appropriate strategy, then data from the double-mutant cycle 
analysis can be collected and used to prove the closed-state hypothesis described above. 
Figure 7.  Above are structures of all the amino acids proposed to be used in the fluorination strategy for 
probing indole NH – backbone carbonyl hydrogen bonds in across the α4-β2 interface.  Below is an 
example of the type of double mutant cycle that could be conducted using NpAla and F
3
Ala. 
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6.4 Computational and Experimental Support for the Fluorination Strategy 
6.4.1 Electrostatic Potential Maps to Predict Hydrogen Bonding Attenuation 
 The hydrogen bond, such as the Loop B-Loop E interaction in question, is 
inherently electrostatic in nature, with the partial positive charge of the hydrogen making 
a stabilizing interaction with the partial negative charge of the hydrogen bond acceptor.  
This phenomenon can be described by the equation log(K) = c1α2Hβ2H + c2 where K is an 
association constant, c1 and c2 are solvent-dependent constants, and α2H and β2H are 
constants that characterize the properties of the hydrogen bond donor and acceptors 
respectively.17 
This relationship can then be rearranged to determine the energetic cost of a 
hydrogen bond donor switching from interacting with solvent to the hydrogen bond 
acceptor.18  Doing so is akin to predicting the free energy of the hydrogen-bonding 
interaction (ΔΔGH-bond), and using the equation ΔΔGH-bond = – (α – αs)(β – βs) will allow 
will allow for the calculation of a hydrogen bond in any solvent provided once these four 
variables are known, as described by Hunter.  All of these parameters can be derived from 
empirically determined α2H and β2H; however, the dimensionless α and β values also 
correspond to the Emax and Emin of electrostatic potential maps determined by density 
functional theory.  The solvent parameters, αs and βs follow the same characteristics, but 
their values have been determined and reported for almost all solvents commonly used in 
the laboratory. 
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Table 4. Results from Computational Electrostatic Potential Map Hydrogen Bond Prediction Studies  
  Emin/max(kJ/mol) α or β* ΔΔGH-bond (kcal/mol) 
Indole 236.8 4.5 Water Hexanes CCl4 DMSO Acetonitrile DMF 
EtAc 175.4 3.4 0.5 -3.1 -2.1 2.1 0.9 0.9 
Ala 205.7 4 0.2 -3.6 -2.5 1.8 0.5 0.5 
Aah 175.3 3.4 0.5 -3.1 -2.1 2.1 0.9 0.9 
F
3
Ala 191.1 3.7 0.3 -3.3 -2.3 1.9 0.7 0.7 
Val 191.5 3.7 0.3 -3.4 -2.3 1.9 0.7 0.7 
Vah 164.5 3.2 0.6 -2.8 -1.9 2.1 1.0 1.1 
F
6
Val 192.4 3.7 0.3 -3.4 -2.3 1.9 0.7 0.7 
* α is calculated for hydrogen bond donors like indole using Emax and β for hydrogen bond acceptors  using Emin 
Figure 8.  Shown are structures and electrostatic potential maps (where red is negative and blue is 
positive) for each compound analyzed by computational methods and NMR experiments with their 
corresponding amino acid in parentheses.  Below each electrostatic potential map in pink are the 
theoretical shifts in binding energy in kcal/mol with the empirical NMR result in parentheses. 
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Thus, the theoretical hydrogen bond strength between an amino acid (or an α-
hydroxy acid) and an indole NH can be determined by generating electrostatic potential 
maps for each molecule and finding the Emax or Emin (depending on whether it is a donor or 
acceptor, respectively).  These energy values are then divided by a correction factor of 52 
kJ/mol to determine the unitless α and β values.  Finally, depending on the solvent of 
interest, ΔΔGH-bond can then be calculated based on the equation above.   
The specific compounds used in these calculations were the same used in the NMR 
studies detailed in the following subsection.  Each compound, except ethyl acetate which 
serves as a control and indole which is the hydrogen bond donor, is an analogue for the 
amino acids proposed in the fluorination strategy double-mutant cycle analysis.  For each 
compound, an electrostatic potential map was generated via an M06 density functional 
theory calculation using a 6-31G(d,p) basis set.  The Emax for indole and Emin for the 
amino/hydroxy acid analogues were then determined and used to calculate α and β, 
ultimately leading to ΔΔGH-bond values for various solvents. 
Because the penultimate read-out in a double-mutant cycle analysis is a fold-shift 
in EC50, the value of interest in these calculations is the relative shift in ΔΔGH-bond from the 
wild-type amino acid to the non-canonical residue, i.e. ΔΔGH-bond (non-canonical) – ΔΔGH-
bond (wild-type).  Thus, the choice of solvent is slightly arbitrary as long as it remains 
consistent in each calculation.  The theoretical ΔΔGH-bond values are reported in Table 4 for 
a wide array of solvents, though carbon tetrachloride was ultimately used to determine 
shifts in ΔΔGH-bond, given in Figure 8.  For the F3Ala analogue, the calculated shift in ΔΔGH-
bond was determined to be 0.22 kcal/mol, about half as attenuating as alanine α-hydroxy 
(Aah).  There was no meaningful calculated shift in ΔΔGH-bond of F6Val compared to Val, 
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with a value of -0.01 kcal/mol.  Valine α-hydroxy (Vah), on the other hand, showed a shift 
in ΔΔGH-bond of 0.39 kcal/mol.  The lack of theoretical hydrogen bond attenuation in F6Val 
is likely due to the weak or nonexistent inductive effects of adding electron-withdrawing 
groups to the γ-carbon.  While these values seem lower than intuition would suggest, these 
computational studies show that relative to Aah, F3Ala is still a promising option for 
probing hydrogen bonds when the i + 1 residue cannot be mutated to an α-hydroxy acid. 
Furthermore, F6Val can serve as a valuable negative control, as it adds electron 
withdrawing fluorine atoms to the side chain without affecting the hydrogen bond. 
6.4.2 Evaluating F3Ala with 19F-NMR 
 Although the previously discussed computational studies show that F3Ala is likely 
a useful non-canonical amino acid for perturbing hydrogen bonds, empirical evidence 
would make this claim stronger.  A 1969 paper by Gurka and Taft reports that the formation 
constant of the hydrogen bond, Kf, can be calculated experimentally through 
19F-NMR.19  
In this experiment, the 19F chemical shift of p-fluorophenol is monitored as a hydrogen 
bond acceptor is added to solution and a donor-acceptor complex is formed.  The 
fluorophenol serves as the hydrogen bond donor, and as the equilibrium of fluorophenol 
and acceptor moves more toward towards donor-acceptor complex, i.e. as the concentration 
of acceptor is increased, the chemical shift of the fluorine will move upfield.  This study 
also showed empirically that Kf follows a van’t Hoff relationship and can be used to 
determine the ΔG of the hydrogen bond interaction.  Precise and accurate Kf measurements 
can be made provided concentrations of the fluorophenol are kept low and that the 
acceptor-donor ratio does not exceed 1:1.  Furthermore, to account for instrument 
variations and other substituent effects, a 0.01 M solution of p-fluoroanisole is used as an 
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internal reference, with changes in chemical shift reported as δ (p-fluoroanisole) – δ (p-
fluorophenol). 
Using this strategy, a dose-response experiment of sorts was conducted by 
incrementally increasing the concentration of hydrogen bond acceptor in a carbon 
tetrachloride solution containing 0.01 M p-fluorophenol and p-fluoroanisole.  As 
concentration of the acceptor was increased, the 19F chemical shift of both the p-
fluorophenol and p-fluoroanisole was monitored, until a 1:1 phenol-acceptor ratio was 
achieved.  The changes in chemical shift follow a sigmoidal shape, with the maximum shift 
Figure 9. Pictured here is a stack of 
19
F-NMR spectra over a range of concentrations of N,N-
dimethylvaleramide, an analogue of Val.  As [Val] increases, more p-fluorophenol is in a hydrogen bond 
complex which causes the peak to shift downfield.  Eventually this effect levels off, yielding a Δ value 
that along with δ, the shift in ppm relative to p-fluoroanisole, and the concentration of Val analogue can 
be used to find K
f
. 
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denoted as Δ.  A Kf value can be determined for each point along the rise of the sigmoidal 
curve using the equation,  
𝐾𝑓 =
[𝑝−fluorophenol]𝑜 (δ/Δ)
[𝑝−fluorophenol]𝑜(1 – (δ/Δ))([acceptor]𝑜 –[𝑝−fluorophenol]𝑜(δ/Δ)) 
, 
where [X]o is the concentration of each hydrogen bonding partner and (δ/Δ) is the chemical 
shift of fluorophenol relative to fluoroanisole at that specific concentration of acceptor 
divided by the maximum shift observed. 
The compounds chosen for this experiment are analogues to the conventional, 
fluorinated, and α-hydroxy forms of the amino acids used in the proposed double-mutant 
cycles (except the F6Val analogue, which did not show attenuating ability in the 
computational studies) and are shown in Figure 8.  These analogues were designed to 
eliminate the amino/hydroxy acid hydrogen bond donor moieties that would complicate 
any results without changing the electrostatic nature of the carbonyl group.  For example, 
N,N-dimethylpropionamide serves as a model compound for alanine as it has a methyl 
group coming off of the α-carbon and an amide bond.  The α-hydroxy acids are modeled 
as esters, and the fluorinated analogues have the appropriate fluorination pattern on the α-
carbon “side chain.”   For each compound, Kf was determined at multiple concentrations 
and averaged. 
A representative set of 19F-NMR spectra for these experiments is shown in Figure 
9 for  N,N-dimethylisovaleramide (Val), while Kf results and corresponding ΔG values are 
reported in Table 5. Using these values the overall ΔΔG of the mutation can be determined 
using the equation ΔΔGmutation = ΔG (non-canonical) – ΔG (wild-type).  Overall, these 
experiments show that an Ala-Aah mutation causes a 1.48 kcal/mol loss in binding energy, 
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Ala-F3Ala a 1.12 kcal/mol loss, and 
Val-Vah a 1.20 kcal/mol loss.  These 
results fall in a more reasonable range 
than the computational study but still 
follow the same trends overall as shown 
in Figure 8.  They definitively show that 
an F3Ala substitution is a solid strategy for attenuating the predicted hydrogen bond at the 
α4-β2 nAChR interface.  Additionally, the oft-used α-hydroxy attenuation strategy is 
further bolstered by these studies. 
6.5 Double-Mutant Cycle Results 
 With the proposed fluorination strategy now grounded in theory and experiment, 
the results from a double mutant cycle analysis utilizing F3Ala can be meaningfully 
interpreted.  Thus, dose response experiments were conducted on receptors expressing the 
following THG73-TQOPS’ combinations to make up the mutant cycle: Trp-Ala as the 
wild-type, NpAla-Ala as the first single-mutant, Trp-F3Ala as the second single-mutant, 
and NpAla-F3Ala as the double mutant.  Results from this cycle (Table 6) show that F3Ala 
has no effect on EC50.  The Trp-Ala and Trp-F3Ala EC50 values are both around 2 μM, and 
the NpAla-Ala and NpAla-F3Ala EC50 values are not meaningfully different.  The Ω value 
 Table 5.  Results from Empirical 
19
F-NMR 
Hydrogen Bonding Studies 
 Kf ΔGH-bond N 
EtAc 18.3 ± 0.3 -1.7 ± 0.1 5 
Ala 214 ± 6 -3.2 ± 0.7 4 
Aah 17.5 ± 0.3 -1.7 ± 0.1 4 
F
3
Ala 32.6 ± 0.9 -2.1 ± 0.2 4 
Val 113 ± 3 -2.8 ± -0.5 5 
Vah 13.9 ± 0.9 -1.6 ± -0.2 5 
 
Table 6. Investigating an Interfacial Hydrogen Bond with a F
3
Ala Mutant Cycle   
α4β2 W149 P120 EC50 (µM) nH Imax (µA) Fold Shift N 
WT Trp Ala 2.18 ± 0.06 1.15 ± 0.03 0.23 - 1.87 1 10 
Mut1 NpAla Ala 0.388 ± 0.008 1.15 ± 0.02 0.35 - 9.92 0.2 14 
Mut2 Trp F3Ala 2.0 ± 0.2 0.75 ± 0.03 0.05 - 1.75 0.9 11 
Mut1,2 NpAla F3Ala 0.62 ± 0.02 0.8 ± 0.02 0.09 - 0.82 0.3 14 
                        Ω 1.7 
ΔΔG (kcal/mol) -0.3 
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calculated from the F3Ala cycle analysis is 1.7, leading to a calculated ΔΔG of around -0.3 
kcal/mol. 
A valine-based mutant cycle was then conducted as a negative control, since F6Val 
was predicted computationally to have no effect on hydrogen bonding ability.  Results for 
this cycle (which are reported in Table 7) show a similar effect, with Trp-Val and Trp-
F6Val having similar EC50 values about 3- to 2-fold greater than NpAla-Val and NpAla-
F6Val.  These values lead to an Ω value of 1.4 and a ΔΔG of -0.2 kcal/mol, results that are 
not that different from the alanine cycle. 
The results from the alanine cycle alone are not large enough to suggest that a 
functional indole-backbone carbonyl hydrogen bond exists here.  However, the evidence 
is even stronger when taking into account that the alanine cycle results are not meaningfully 
different from the negative control valine results.  If the valine cycle ΔΔG value is treated 
as a baseline, the alanine cycle then has an adjusted ΔΔG of -0.1 kcal/mol.  Remember that 
weak hydrogen bonds, like those typically found inside a protein, are typically on the order 
of 0.5 – 1.5 kcal/mol,20 and that the hydrogen bond between nicotine and a backbone 
carbonyl on Loop B was determined to be around 2.5 kcal/mol in strength (Chapter 4).  
Furthermore, the NMR studies presented in this chapter predicted the hit from attenuating 
the hydrogen bond between an alanine and indole with F3Ala to be worth 1.12 kcal/mol.  
Table 7. F
6
Val Double Mutant Cycle Negative Control for Interfacial Hydrogen Bond Studies 
α4β2 W149 P120 EC50 (µM) nH Imax (µA) Fold Shift N 
WT Trp Val 2.08 ± 0.07 1.2 ± 0.04 0.13 - 5.54 1 15 
Mut1 NpAla Val 0.65 ± 0.01 1.16 ± 0.02 1.25 - 6.36 0.3 13 
Mut2 Trp F6Val 2.1 ± 0.2 0.78 ± 0.03 0.07 - 29.91 1.0 13 
Mut1,2 NpAla F6Val 1.22 ± 0.08 0.77 ± 0.02 0.11 - 1.96 0.6 11 
                        Ω 1.9 
ΔΔG (kcal/mol) -0.4 
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That the adjusted ΔΔG from double-mutant cycles is only 0.1 kcal/mol heavily suggests 
the initial hypothesis that a Loop B-Loop E interfacial hydrogen bond somehow stabilizes 
the closed state is wrong, and that the gain of function observed with the TrpB to NpAla 
mutation is due to some other effect. 
6.6 Studies with 3-Benzothiophene 
 Though the specific cause remains unclear for the gain of function observed when 
mutating the TrpB indole ring into a napthyl ring, it can be said with some certainty that 
the shift is not due to disrupting a TrpB hydrogen bond with the Leu119 carbonyl on Loop 
E.  It could be quite possible the gain of function has nothing to do with a hydrogen bond 
at all, that the change in EC50 could be due to another perturbation in the binding pocket 
caused by NpAla.  One way to address this question would be through a 3-benzothiophenyl 
Figure 10. A schematic showing the effects of 3-benzothiophene mutation designed to eliminate a 
potential indole NH hydrogen bond without affecting the geometry of the side chain. 
Table 8.  3-Benzothiophene Substitution at TrpB to Probe for Interfacial Hydrogen Bond 
  EC50 (µM) nH Imax (µA) Fold Shift N 
Trp 0.6 ± 0.01 1.19 ± 0.03 1.87 - 5.33 1.0 11 
3-BTA 8.0 ± 0.3 1.38 ± 0.05 0.99 - 13.37 13 17 
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alanine (3-BTA) mutation that essentially substitutes the indole nitrogen with a sulfur atom, 
thus eliminating any possible hydrogen bond without changing the geometry of the ring 
system (although sulfur is much larger than nitrogen). 
 A 3-BTA substitution was conducted using nonsense suppression at TrpB in the α4 
subunit to determine whether the NpAla effect is due to hydrogen bonding, and the 
mutation actually showed a 13-fold increase in EC50 (Table 8).  This loss of function is in 
direct contradiction with the NpAla results, which showed a 5-fold decrease in EC50.   
Perhaps then, these changes in function are due to some other reason such as electrostatics.  
It is important to remember that both the NpAla and 3-BTA mutations bring a change in 
electrostatics and thus the cation-π binding ability of the side chain.  Using Hartree-Fock 
computations in order to remain consistent with other α4β2 studies, Trp, NpAla, and 3-
BTA have ab initio Na+ binding energies of 32.6, 28.9, and 26.9 kcal/mol, respectively.  
Previously reported fluorination plots can be used to calculate the expected EC50 values 
based on these predicted binding energies, reported here in Table 9.  Eliminating 
electrostatics as a factor, NpAla now causes a 10-fold shift in EC50 less than what is 
expected, while the 3-BTA shift becomes a more modest 4-fold greater than expected.  
Therefore, it is unlikely that electrostatics are causing the effect either. 
Table 9. Comparing Experimental EC
50
 Values to those Predicted from α4β2 TrpB Fluorination Plot 
  
ab initio 
binding energy 
Predicted EC
50
 Empirical EC
50
 Fold-Shift 
(from prediction) 
Trp 32.6 0.52 0.54 1.0 
NpAla 28.9 1.21 0.12 0.1 
3-BTA 26.9 1.92 8 4.2 
ab initio values from HF 6-31G** calculations;  predicted EC
50
 based on published fluorination plot with 
trend line 3.24 - 0.10x; 
Fold-shift = Empirical EC
50 
/ Predicted EC
50
;  
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6.7 Conclusions 
 It seems legitimately possible that a combination of all of the above could explain 
the NpAla gain of function.  The only other electrostatics-corrected gain of function 
reported at TrpB in this thesis occurred in α6β2‡ with 4-F1Trp, which had an EC50 about 4-
fold lower than expected based on electrostatics.  This effect was largely ignored as it was 
the only Trp analogue with a substituent in the 4-position.  It is also unclear if this mutation 
would have the same effect in α4β2; however, assuming that it did, the NpAla mutation 
adds an ever so slightly greater steric bulk on the same edge of the ring as the 4-postion 
and could be driving a similar effect. 
Many more experiments and structure-function studies would be necessary to prove 
this rather hand-wavy hypothesis, but it is probably worth exploring in the future.  While 
the mystery of what might be causing the NpAla gain of function still lingers, new 
techniques have been developed in the process.  For the first time, two different non-
canonical amino acids have been incorporated in a neuronal nAChR, a technique that can 
likely be applied to other potential interactions and in different neuronal nAChR subtypes.  
Furthermore, the fluorinated side chain approach to probing hydrogen bonds was proven 
to be viable through both computational and empirical methods.  A positive result would 
have definitively proven the validity of F3Ala as a means of attenuating a carbonyl’s 
hydrogen bond accepting ability, but the end result was negative, so a positive control 
should be developed to make absolutely certain of its functionality.  This could prove quite 
difficult since the only nAChR carbonyl known to make a functional hydrogen bond is 
associated with TrpB, which also makes a critical cation-π interaction.  However, results 
in Chapter 5 suggest that maybe a secondary amine that forms cation-π interactions with 
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both TrpB and TyrC2 could tolerate a Trp-to-Ala mutation and thus a Trp-to-F3Ala 
mutation.  Even without the positive control, a technique has been developed in this chapter 
that will hopefully prove to be a valuable strategy for probing hydrogen bond interactions 
both between amino acids and possibly with agonists. 
6.8 Materials and Methods 
Molecular Biology 
Rat α4L9’A (described as wild-type and/or α4 throughout this chapter) and β2 nAChRs 
were in the pGEMhe vector, a cDNA plasmid optimized for protein expression in Xenopus 
oocytes.  Site-directed mutagenesis was performed by PCR using the Stratagene 
QuikChange protocol and primers ordered from Integrated DNA Technologies (Coralville, 
IA).  Circular cDNA was linearized with SbfI (New England Biolabs, Ibswich, MA) and 
then transcribed in vitro using T7 mMessage mMachine kit (Life Technologies, Santa 
Clara, CA), with a purification step after each process (Qiagen, Valencia, CA).  Final 
concentrations were quantified by UV spectroscopy. 
Ion Channel Expression 
Xenopus laevis oocytes (stage V to VI) were sourced from both a Caltech facility and 
Ecocyte Bio Science (Austin, TX).  Oocytes were injected with 50 nL solution containing 
either 5 or 10 ng mRNA.  The α4L9’A:β2 mRNA mass ratio and was typically 1:3 for wild-
type and conventional mutagenesis experiments.  Cells were incubated 24-48 hours at 18oC 
in ND96 solution (96 mM NaCl, 2mM KCl, 1 mM MgCl2, and 5mM HEPES, pH 7.5) 
enriched with theophylline, sodium pyruvate, and gentamycin. 
Non-canonical Amino Acid Incorporation 
The cyanomethylester form of NVOC-protected tryptophan, leucine, alanine, and valine 
and their corresponding analogues was coupled to dinucleotide dCA and enzymatically 
ligated to either UAG-suppressor 74-mer THG73 tRNACUA or UGA-suppressor 74-mer 
TQOPS’UCA as previously described.21  The product was verified by MALDI time-of-flight 
mass spectrometry on a 3-hydroxypicolinic acid matrix.  The non-canonical amino acid-
coupled tRNA was deprotected by photolysis on a 500 W Hg/Xe arc lamp, filtered with 
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Schott WG-320 and UG-11 filters, immediately prior to coinjection with mRNA containing 
the UAG or UGA mutation at the site of interest.  mRNA and tRNA were typically injected 
in a 1:1 or 1:2 volume ratio in a total volume of 50 or 75 nL respectively so that 25 ng of 
mRNA was injected per cell. 
For double mutant experiments α4L9’AW149TAGβ2L119TGA was injected at a 1:10 
mRNA ratio to maintain a (α4)2(β2)3 stoichiometry and confirmed via the Hill coefficient 
(cases of a shift in stoichiometry resulted in a large increase in this value).  In cases where 
observed agonist-induced currents were low after 48 hour incubation – likely due to low 
receptor protein expression – a second injection of mRNA and tRNA was performed after 
24 hours.  The fidelity of non-canonical amino acid incorporation was confirmed at Trp149, 
Leu119, and Pro120 with the wild-type recovery and 76-mer experiments described above. 
Whole-Cell Electrophysiological Characterization 
Acetylcholine chloride and lobeline were purchased from Sigma Aldrich (St Louis, MO).  
Agonist-induced currents were recorded in TEVC mode using the OpusXpress 6000A 
(Molecular Devices, Sunnyvale, CA) at a holding potential of -60 mV in a running buffer 
of Ca2+-free ND96.  Agonists were prepared in Ca2+-free ND96 and delivered to cells via 
a 1 mL application over 15 sec followed by a 2 min wash.  Data from dose-response 
experiments were normalized, averaged, and fit to the Hill equation using Kaleidagraph 
(Synergy Software, Reading PA), though data are visualized here with Prism (GraphPad 
Software, La Jolla, CA).  Error bars are presented as standard error of the mean, while EC50 
and Hill coefficient errors are reported by Kaleidagraph and represent the sum of the 
squared error between the data and the calculated fit. 
Computational Evaluation of Hydrogen Bonding 
All calculations were performed in Spartan ’14 (Wavefunction Inc., Irvine, CA) using 
density functional theory with the M06 functional and the 6-31G(d,p) basis set.  
Electrostatic potential maps with high resolution were calculated using the Spartan ‘14 
graphical user interface.  Electrostatic potential maxima (for indole) and minima (for the 
acceptors) were determined, and the α, β, and ΔΔGH-bond values were calculated using 
methods described in section 6.4.1 with values for αs and βs sourced from previously 
published work.18 
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NMR Determination of Hydrogen Bond Acceptor Strength 
All compounds were either purchased from Sigma Aldrich (St Louis, MO) or synthesized 
using published methods.  Solutions of p-fluorophenol and p-fluoroanisole, both at 0.01 
M, and hydrogen bond acceptor in varying concentrations were prepared in purified carbon 
tetrachloride.  19F-NMR measurements were taken on a 400 MHz instrument (Varian 
Associates, Palo Alto, CA).  Kf was calculated as described in section 6.4.2 and ΔG was 
determined using the van’t Hoff equation, ΔG = -RTln(Kf). 
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Appendix A: Investigations of Possible α6β2-P2X Cross-talk††  
A.1 Introduction 
 In addition to regulating dopamine release in the brain, α6-containing nAChRs are 
also involved in nociception.  In a large mouse study, mechanical allodynia, a type of 
chronic neuropathic pain that results in a sensitized response to innocuous stimuli, was 
found to correlate with expression levels of the Chrna6 gene (which codes for α6) in the 
dorsal root ganglia.1  This study found that Chrna6-knockout mice showed higher levels 
of allodynia than wild-type mice, an effect that was absent in Chrna4-knockouts.  
Conversely, mice with a Chrna6 L9’S gain-of-function mutation experienced lower levels 
of allodynia.  These results reveal an anti-allodynic effect of α6-containing nAChR 
activation and suggest a functional interaction between α6 and a more pain-relevant 
molecular target in the peripheral nervous system, such as the P2X receptors. 
 The P2X family consists of ATP-gated ion channels formed by three subunits.  
Each subunit has two transmembrane helices and intracellular N- and C-terminal domains.  
There are seven different subunits, labeled P2X1-P2X7, that like nAChRs combine into 
different subtypes.  Dorsal root ganglion neurons express homomeric P2X2, P2X3, and 
heteromeric P2X2/3 receptor subtypes.2  Previous work in Xenopus ooyctes has shown that 
α6β4 experiences several forms of functional crosstalk with P2X2, P2X3, and P2X2/3.3  
The P2X2 receptors were found to enter a prolonged desensitized state upon activation by 
ATP when coexpressed with α6β4, resulting in cross-inhibition.  That is, when ACh was 
                                                 
†† The dose-response work presented in this appendix is adapted, with permission, from: 
Wieskopf, J.S. et. al. The nicotinic α6 subunit gene determines variability in chronic pain sensitivity via 
cross-inhibition of P2X2/3 receptors. Science Translational Medicine 7:287 287ra72 (2015). 
doi:10.1126/scitranslmed.3009986 
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applied to the receptors following a dose of ATP, there was an observed decrease in current.  
Additionally, when ACh and ATP were applied simultaneously, the induced current was 
less the sum of the currents invoked from individual application of each agonist.  When 
α6β4 was coexpressed with P2X3, cross-talk was seen through dose response experiments.  
The ATP dose response curve was shifted to the right, with a roughly 3-fold increase in 
EC50 both in the presence and absence of ACh. 
 With the development of the α6β2‡ heterologous expression system, these 
experiments could be repeated with α6β2 to determine whether there is a similar cross-
interaction with P2X receptors.  The data presented in this appendix suggest that there is 
an effect with P2X2, though results for P2X3 raise perhaps more questions than they could 
answer. 
Table 1.  Investigating α6β2-P2X2 and α6β2-P2X3 Interactions through Dose-Response Effects 
Receptor 
Dose-Response 
Agonist 
Additional 
Agonist EC50 (μM) nH Imax (μA) N 
P2X2* ATP  24 ± 1 1.5 ± 0.1     
P2X3* ATP  38 ± 6 0.9 ± 0.1     
α6β2
‡ ACh   0.121 ± 0.006 1.12 ± 0.05 1.32 - 14.09 15 
α6β2
‡ ACh 100 µM ATP 0.121 ± 0.003 1.33 ± 0.05 2.38 - 19.67 14 
α6β2
‡
-P2X2 ACh   0.15 ± 0.01 1.17 ± 0.08 0.79 - 4.93 11 
α6β2
‡
-P2X2 ACh 100 µM ATP 0.3 ± 0.06 1.3 ± 0.3 0.75 - 2.42 11 
α6β2
‡
-P2X2 ATP   26 ± 2 1.6 ± 0.2 0.18 - 13.42 14 
α6β2
‡
-P2X2 ATP 10 µM ACh 29 ± 2 1.9 ± 0.2 0.12 - 6.52 12 
α6β2
‡
-P2X3 ACh   0.127 ± 0.006 1.19 ± 0.05 0.2 - 9.22 11 
α6β2
‡
-P2X3 ATP   44 ± 7 0.9 ± 0.1 0.17 - 3.5 13 
*P2X data previously reported in Limapichat et al 
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A.2 α6β2-P2X2 Cross-talk Experiments 
 To investigate whether functional cross-talk exists between α6β2 and P2X2, dose 
response experiments were conducted with ACh and ATP at α6β2‡, P2X2, and coexpressed 
α6β2‡-P2X2.  Then, dose response curves were generated for ACh in the presence of ATP 
as well as ATP in the presence of ACh.  Results from these experiments are shown in Table 
1 and reveal that the presence of P2X2 has no meaningful effect on either the ATP- or the 
ACh-generated dose response curves. 
 Instead, functional cross-talk between α6β2 and P2X2 is observed in cross-
inhibition Delta tests.  In these experiments, ACh and ATP are applied in independent 
doses followed by a dose of both ACh and ATP.  The current evoked from the ACh+ATP 
dose is then compared to the current level predicted from the sum of each independent 
current amplitude.  Nonadditivity of these two currents would suggest functional cross-
inhibition of the two receptors.  For α6β2 and P2X2, the dual agonist-invoked current is 
19% percent smaller than expected (represented by Delta, Figure 1), supporting the idea 
that these two receptors are involved in cross-inhibition. 
Figure 1. Results from a Delta test to determine 
whether α6β2 and P2X2 functionally interact with 
each other.  In this test, ACh and ATP are applied 
to cells expressing both receptors in independent 
doses with a washout step in between.  The 
currents generated from these doses are added and 
normalized to create the predicted current 
column, assuming perfect additivity.  Then, a 
combined ACh and ATP dose is applied to the 
same cells.  The difference in this current and the 
predicted current result in the Delta value.  A 
paired t-test was used to determine whether there 
was a statistical difference between the combined 
dose current and the predicted current (P<0.0001, 
N=12). 
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A.3 α6β2-P2X3 Cross-talk Experiments 
 To test whether α6β2 and P2X3 engage in cross-talk, dose response curves were 
generated for each subtype individually and while coexpressed (Table 1).  From these 
experiments there is little evidence of α6β2-P2X3 cross-talk as there are no meaningful 
shifts in EC50 observed.  It is important to note that P2X3 is a quickly desensitizing receptor 
subtype, and studying the effects of dual agonist applications is challenging.  To do this, 
Figure 2. The top left trace is representative of P2X3 activation by ATP. In each of the other current 
traces, ACh is added to the cells by perfusion over one minute and a dose of ATP (or ACh in the fluidics 
control on the top center) is added by the liquid handler over 2 sec.  As shown here, a concentrated dose 
of ATP causes a large inhibitory spike at α6β2-P2X3, α4β2-P2X3, and α6β2 alone.  With fluidics effects 
ruled out, this suggest ATP is able to channel block β2-containing nAChRs.  
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ACh is delivered to cells by the buffer perfusion system and a mixture of ATP and ACh is 
applied by the liquid handler as is typical, followed by perfusion with only ACh, and then 
a wash-out with buffer (this protocol was followed for most traces shown in Figure 2).  
This is the identical experimental set up used for the α6β4 experiments; however, a strange 
inhibition-like peak is observed in the current trace at high concentrations of ATP when 
α6β2‡ and P2X3 are coexpressed, that disappears as ATP is washed out with ACh.  At first 
this was thought to be a fluidics issue; however, the same phenomenon is absent when an 
ACh-only dose is applied via the liquid handler.  The next most-rational explanation is that 
activation of P2X3 by ATP causes an immediate but temporary deactivation of α6β2.  This 
could be due a direct interaction with β2, as the same effect is seen in α4β2-P2X3 
expressing cells as well.  Yet, a control experiment where only α6β2‡ is expressed also has 
the same result.  This then suggests that ATP acts as a channel blocker for β2-containing 
nAChR subtypes. More work must be done to fully resolve the cause of this unexpected 
result.  If ATP does indeed channel block certain subtypes of nAChRs, it would have 
interesting consequences for the understanding of neurotransmission. 
A.4 Materials and Methods 
Ion Channel Expression 
Rat α4L9’A (described as α4 throughout), β2,  α6L9’S and β2L9’SLFM/AAQA nAChRs were 
in the pGEMhe vector, a plasmid optimized for protein expression in Xenopus oocytes.  
P2X2 and P2X3K65A (referred to as P2X3 throughout the appendix) were in the pcDNA3 
vector.  Xenopus laevis oocytes (stage V to VI) were sourced from both a Caltech facility 
and Ecocyte Bio Science (Austin, TX).  Oocytes were injected with 50 nL solution 
containing 5 ng mRNA in a 10:10:1 ratio for α6β2-P2X2 and a 1:1:1 ratio for α6β2-P2X3.  
Cells were incubated 24-48 hours at 18oC in ND96 solution (96 mM NaCl, 2mM KCl, 1 
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mM MgCl2, and 5mM HEPES, pH 7.5) enriched with theophylline, sodium pyruvate, and 
gentamycine. 
Whole-Cell Electrophysiological Characterization 
Acetylcholine chloride, and ATP disodium salt hydrate were purchased from Sigma 
Aldrich (St Louis, MO).  Agonist-induced currents were recorded in TEVC mode using 
the OpusXpress 6000A (Molecular Devices, Sunnyvale, CA) at a holding potential of -60 
mV in a running buffer of Ca2+-free ND96.  Agonists were prepared in Ca2+-free ND96; 
ACh was either delivered to cells via a 1 mL application over 15 sec or through the buffer 
perfusion system; ATP was delivered via a 1 mL application over 15 sec for P2X2 or a 0.5 
mL dose over 5 sec for P2X3.  Data from dose-response experiments were normalized, 
averaged, and fit to the Hill equation using Kaleidagraph (Synergy Software, Reading PA), 
though data is visualized here with Prism (GraphPad Software, La Jolla, CA).  Data from 
delta experiments were normalized to the predicted current and averaged.  A pair-wise t-
test was used to determine significance between ATP+ACh and predicted currents.  Error 
bars are presented as standard error of the mean, while EC50 and Hill coefficient errors are 
reported by Kaleidagraph and represent the sum of the squared error between the data and 
the calculated fit. 
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Appendix B:  Initial Studies of Alcohol-α6β2 Interactions  
B.1 Introduction 
 For a long time, it was believed that ethanol acts as an unspecific pharmacological 
agent.  The last few decades have definitively proven otherwise, with several ligand-gated 
ion channel targets identified, including NMDAR glutamate receptors, GABAA receptors, 
glycine receptors, and nAChRs.1  In nAChRs, ethanol typically has a concentration-
dependent potentiating effect, i.e. it acts as a positive allosteric modulator.  This is true for 
concentrations less than 100 mM‡‡ with α2β4, α4β4, α2β2, and α4β2, and all of the 
subtypes studied (though α6β2 is notably absent from these surveys) for concentrations 
greater than 100 mM.2 
This observation is actually a result of a more comprehensive chain length effect: 
as the chain length of the alcohol increases, the effect of the alcohol shifts from potentiating 
to inhibitory, with each subtype having a unique transitional chain length wherein the effect 
actually changes as the concentration increases.3  In α4β2, the total amount of potentiation 
or inhibition was plotted against chain length, and a corresponding ΔΔG was calculated to 
be 0.4 kcal/mol/CH2 for potentiation and 0.8 kcal/mol/CH2 for inhibition.
4  That there were 
two distinct ΔΔG values suggests there are two definitive binding sites depending on the 
molar volume of the alcohol.  The effects of ethanol on α4β2 have also been studied using 
single channel analysis.  These experiments showed a shift in Popen from 0.023 to 0.029 in 
the presence of ethanol.5 
                                                 
‡‡ For reference, a 0.08 blood alcohol concentration (the legal limit for driving drunk) is the equivalent of 
17.4 mM. A value of 0.50, the lower end of the BAC spectrum that leads to death from alcohol poisoning, is 
equivalent to a concentration of 108.7 mM. 
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Most of the research conducted on nAChRs and alcohols date back to the 1990s 
and early 2000s.  Recently, however, studies are emerging revealing the role α6-containing 
receptors have on the behavioral effects of ethanol.  A 2012 knockout study showed that 
α6 modulates ethanol’s sedative effects, and a 2013 study showed L9’S mutant mice show 
a higher preference for alcohol in behavioral studies.6,7 In 2015, a paper showed that co-
application of nicotine and ethanol was enough to elicit response from AMPA receptors 
even when the nicotine concentration would typically lie below the threshold required to 
cause such a response.  However, this effect was blocked by α6-selective MII conotoxin 
antagonist.8  Reports have also been published beginning to hypothesize the location of 
discreet binding sites in pLGIC receptors.  The M2 helix 15’ position in GABAA and GlyR 
have shown some sensitivity to the effects of alcohol as have the 16’ and 17’ positions in 
nAChRs.  In GLIC, structural data suggests a phenylalanine at the 14’ position is a possible 
ethanol binding site.9  
With mounting evidence that α6β2 plays a substantial role in how the brain 
processes ethanol, new clues leading toward a possible specific binding site, and a well-
optimized heterologous expression system discussed in Chapter 2, the pieces are in place 
Figure 1. A typical current trace from tests used to determine the allosteric effect of an alcohol on α6β2.  
An initial dose of ACh is followed by an incubation period of just alcohol.  A second dose of ACh plus 
alcohol is applied, and the percent difference in current is determined. 
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to both characterize the effects that ethanol and other alcohols have on α6β2.  Using α6β2‡, 
the effects of various alcohols can be catalogued, and structure-function studies using non-
canonical amino acid mutagenesis could be conducted to fully characterize ethanol 
binding.  This appendix details initial experiments done in that vein and possible 
experiments to conduct going forward. 
B.2 Determining the Allosteric Effects of EtOH at α6β2 
 Because the α6β2 subtype was absent from previously published work, it was 
unclear where on the chain-length spectrum the potentiation-inhibition transition point 
might occur.  Thus, methanol, ethanol, and isopropanol were studied at α6β2‡.  In this 
experiment, an application of ACh is applied after which the cell is incubated in the alcohol 
Figure 2. A scatter plot depicting the effect various alcohols have on α6β2 and α4β2.  The horizontal line 
shows the mean, with error bars representing the standard error of the mean.  Note that only isopropanol 
has a meaningful effect at α6β2.  The trends seen in α4β2 data agree with previously published results. 
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of interest for two minutes. This period is followed by an application of both the alcohol 
and ACh and finally a washout step (Figure 1).  The percent difference in current amplitude 
between the ACh and ACh+ROH peaks is then determined.  If that number is positive the 
alcohol has a potentiation effect, whereas a negative percent difference in current 
amplitudes means the alcohol is inhibitory.  Results were collected at α4L9’Aβ2 to verify 
the method, and the general trends are consistent with what is published (though 
differences in effect magnitude are likely due to the presence of the L9’A mutation which 
was not present in the original study).  The results from α6β2‡ show that only isopropanol 
has any meaningful effect on current level, a 33±1% decrease in current (Figure 2). 
That no effects were seen with ethanol or methanol suggests the so-called transition 
point could be near these chain lengths. It is also possible that the concentrations used for 
these tests were outside the effective range.  Thus, a dose response experiment was 
Figure 3. Results from a dose response experiment (N=16) for ethanol at α6β2
‡
.  The percent difference 
in current between a control dose of ACh and an ACh+EtOH dose after two minutes of incubation is 
plotted against the corresponding concentration of ethanol.  While there are no obvious trends or 
correlations here, there is a general though modest potentiating effect seen here that was not in the 
previous chart (Figure 2). 
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conducted with ethanol at α6β2‡ using the same protocol described above, but with 
increasing concentrations of ethanol.  The resulting plot of percent difference in current 
against concentration of ethanol shows no apparent trends, other than modest potentiation 
at certain concentrations (Figure 3). 
This lack of effect is incongruous with the previously published neurological and 
pharmacological studies discussed above.  It could be due to a number of factors, though 
additional work is required to fully understand these results.  Dose response curves should 
be generated for other alcohols of varying chain lengths in order to determine this subtype’s 
transitional chain-length.  Because these effects are likely causing changes in gating, 
single-channel analysis would also be useful to determine what effect each alcohol has on 
Θ, Popen, and the general kinetics of the receptor. 
If a trend is eventually observed, non-canonical amino acid mutagenesis could be 
used to determine the specific binding site of these alcohols.  There is a Phe in the M2 helix 
at position 14’ in both α6 and α4 that, based on studies in GLIC and GABAAR, could be a 
likely target.  If so, ethoxyphenylalanine might prove to be an effective analogue to mimic 
ethanol-bound receptor.  TEVC experiments could determine the potentiation effects while 
single channel analysis could determine the Popen for the mutant, wild-type, and wild-type 
in the presence of ethanol.  If F14’ is indeed responsible for ethanol binding, a fluorination 
series could then be conducted to determine if the binding interaction is a polar-π 
interaction between the hydroxyl and the aromatic side chain. 
Based on the literature, studying alcohol effects at α6β2 should be fertile ground 
for new experiments and important findings.  However, it is clear that further optimization 
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of the protocols and a better understanding of ethanol’s basic effects on the receptor are 
necessary before comprehensive studies can be performed. 
B.3 Materials and Methods 
Ion Channel Expression 
Rat α4L9’A (described as α4 throughout), β2,  α6L9’S and β2L9’SLFM/AAQA nAChRs 
were in the pGEMhe vector, a plasmid optimized for protein expression in Xenopus 
oocytes.  Xenopus laevis oocytes (stage V to VI) were sourced from both a Caltech 
facility and Ecocyte Bio Science (Austin, TX).  Oocytes were injected with 50 nL 
solution containing 5 ng mRNA in a 10: 1 ratio.  Cells were incubated 24-48 hours at 
18oC in ND96 solution (96 mM NaCl, 2mM KCl, 1 mM MgCl2, and 5mM HEPES, pH 
7.5) enriched with theophylline, sodium pyruvate, and gentamycine. 
Whole-Cell Electrophysiological Characterization 
Acetylcholine chloride, methanol, and isopropanol were purchased from Sigma Aldrich 
(St Louis, MO).  Koptec 200 proof ethanol (Decon Labs, King of Prussia, PA) was used 
to make ethanol solutions.  Agonist-induced currents were recorded in TEVC mode using 
the OpusXpress 6000A (Molecular Devices, Sunnyvale, CA) at a holding potential of -60 
mV in a running buffer of Ca2+-free ND96.  Agonists and alcohols were prepared in Ca2+-
free ND96 and applied according to protocols discussed above.  Data from dose-response 
experiments were normalized, averaged, and fit to the Hill equation using Kaleidagraph 
(Synergy Software, Reading PA), though data is visualized here with Prism (GraphPad 
Software, La Jolla, CA).  Error bars are presented as standard error of the mean.  
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